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ABSTRACT 
 
 
 Invasive aspergillosis is a leading cause of morbidity and mortality among 
immunocompromised populations and is predicted to cause more than 200,000 life-
threatening infections each year. Aspergillus fumigatus is the most prevalent pathogen 
isolated from patients with invasive aspergillosis, accounting for more than 60% of all 
cases. Currently, the only antifungal agents available with consistent activity against A. 
fumigatus are the mold-active triazoles and amphotericin B, of which the triazoles 
commonly represent both front-line and salvage therapeutic options. Unfortunately, the 
treatment of infections caused by A. fumigatus has recently been further complicated by 
the global emergence of triazole resistance among both clinical and environmental 
isolates, and a large proportion of this resistance remains unexplained.  
 
In this work, we characterize the contributions of previously identified 
mechanisms of triazole resistance, including mutations in the sterol-demethylase-
encoding gene cyp51A, overexpression of sterol-demethylase genes, and overexpression 
of the efflux pump-encoding gene abcC, among a large collection of highly triazole-
resistant clinical A. fumigatus isolates. Upon revealing that these mechanisms alone 
cannot substantiate the majority of triazole resistance exhibited by this collection, we 
then characterize the direct contribution of two additional efflux pump-encoding genes, 
abcA and atrI. Increased expression of abcA and atrI has previously been associated with 
triazole resistance in clinical isolates of A. fumigatus, and both of these genes exhibit a 
high degree of homology with the well characterized Candida albicans triazole efflux 
pump-encoding gene, CDR1. However, deletion of either abcA or atrI in triazole-resistant 
clinical isolates which overexpress these genes, did not result in a significant change in 
triazole susceptibility.   
 
Finally, upon demonstrating that the canonical mechanisms of triazole resistance 
poorly explain the high level of triazole resistance observed in this collection of clinical 
isolates, we subsequently describe the identification and characterization of a novel 
genetic determinant of triazole resistance. Mutations in the HMG-CoA reductase 
encoding gene, hmg1, were identified in a majority of triazole-resistant clinical isolates in 
our collection. Introduction of three different hmg1 mutations, predicted to encode 
residue alterations in the conserved sterol sensing domain of Hmg1, resulted in 
significantly increased resistance to the triazole class of agents. Additionally, correction 
of an hmg1 mutation in a pan-triazole-resistant clinical isolate of A. fumigatus with a 
novel Cas9-ribonucleoprotein (RNP) mediated system, was shown to restore clinical 
susceptibility to all triazole agents. Mutations in hmg1 were also shown to lead to the 
accumulation of ergosterol precursors, such as eburicol, by sterol profiling, while not 
altering the expression of sterol-demethylase genes. Taken together, the findings 
described in this work serve to demonstrate that mutations in hmg1 are a common and 
significant genetic determinant of triazole resistance in clinical isolates of A. fumigatus.  
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CHAPTER 1.    THE EMERGING THREAT OF TRIAZOLE-RESISTANT 
ASPERGILLUS FUMIGATUS* 
 
 
Introduction 
 
Invasive aspergillosis is a leading cause of morbidity and mortality among 
immunocompromised patient populations, such as patients receiving solid organ or stem 
cell transplants, patients with hematologic malignancies, and those taking 
immunosuppressive agents.[1] Aspergillus, the causative agent of invasive aspergillosis, 
is a genus of septate, saprophytic mold containing hundreds of identified species. Of 
these only Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, and Aspergillus 
niger commonly cause disease in humans, with A. fumigatus representing more than 60% 
of all clinical isolates.[2] Worldwide, invasive aspergillosis is conservatively estimated to 
cause more than 200,000 life threatening infections each year.[1, 2] Mortality rates range 
considerably, from 30- 90%, varying by patient population as well as severity and 
duration of immunosuppression.[3-5] Unfortunately, the treatment of infections caused 
by A. fumigatus has recently been further complicated by the global emergence of triazole 
resistance among both clinical and environmental isolates.[6-9] 
 
 
The Mold-Active Triazoles 
 
Since the widespread introduction of itraconazole to clinical practice in 1992, the 
mold-active triazole antifungals have been utilized as both front-line and salvage 
therapeutic agents for the treatment of invasive aspergillosis. Voriconazole is now 
considered the therapy of choice, and is available in both intravenous and oral 
formulations.[10] Multiple studies comparing the efficacy of voriconazole to that of the 
previous standard of care, amphotericin B, have found voriconazole to be more 
efficacious and generally safer than either conventional (deoxycholate) or lipid 
formulations of amphotericin B.[11, 12] Isavuconazole was recently approved for the 
treatment of invasive aspergillosis, after demonstrating non-inferiority to the standard of 
care, voriconazole.[4, 10] Isavuconazole, as the prodrug isavuconazonium sulfate, is 
available in both intravenous and oral formulations.[13] Posaconazole, often used as 
prophylaxis against invasive fungal infections in high-risk patients such as those with 
acute myeloid leukemia, is also employed as second-line or salvage therapy for invasive 
aspergillosis, and is now available in both intravenous and delayed-release tablet 
formulations. Itraconazole is still used commonly worldwide, but its use in invasive 
aspergillosis has decreased due to both lower anti-aspergillus potency and the withdrawal 
of intravenous formulations from some markets.[10] While all these agents possess a  
 
----------------- 
* Reprinted from final submission with permission. Rybak JM, Fortwendel JR, and 
Rogers PD. Emerging threat of triazole-resistant Aspergillus fumigatus. J Antimicrob 
Chemother. 2019 Apr 1;74(4):835-842. doi: 10.1093/jac/dky517 By permission of 
Oxford University Press.  
 2 
triazole active moiety (from which this class of agents gained its name), they can be 
grouped into two distinct pharmacophores (Figure 1-1). The compact triazoles such as 
voriconazole and isavuconazole consist of a triazole ring linked to aromatic groups such 
as difluorobenzine via a four-carbon backbone. While the extended side-chain triazoles, 
including itraconazole and posaconazole, possess both a halogenated phenyl ring as well 
as a long lipophilic side-chain comprised of five and six membered aromatic rings 
terminating in a triazolone group. The structural distinctions between these agents are 
thought to contribute to differences in stabilizing interactions sterol-demethylase 
enzymes. 
 
 
Mechanism of Action of the Triazoles 
 
In fungi, ergosterol is a key membrane lipid similar to mammalian cholesterol. 
Under normal growth conditions, ergosterol is plentiful in the fungal cell membrane and 
contributes to membrane integrity and fluidity, as well the appropriate positioning of 
fungal proteins within the membrane. The triazoles exert antifungal activity by blocking a 
key enzymatic step in the biosynthesis of ergosterol. Through direct interaction between 
N4 of the triazole ring and an iron atom present in the catalytic heme group, the triazoles 
competitively inhibit sterol-demethylase enzymes (Figure 1-2). Inhibition of sterol-
demethylase, such as Cyp51A and Cyp51B in the case of A. fumigatus, leads to the 
diversion of ergosterol precursors from the normal biosynthetic pathway and 
accumulation of alternative sterols including toxic 14⍺-methylated sterols. It is believed 
that this depletion of ergosterol and buildup of 14⍺-methylated sterols ultimately leads to 
inhibition of fungal growth.[14] 
 
A. fumigatus possesses two genes which encode homologous but distinct sterol-
demethylase enzymes, cyp51A and cyp51B. These genes share approximately 60% 
sequence identity, however the triazole antifungals have been observed to have 
significantly lower binding affinity for the Cyp51A enzyme.[15, 16] This reduced 
binding affinity is due in large part to the threonine amino acid present at position 301 
(T301) of Cyp51A, which replaces the more common isoleucine residue present at this 
position in other fungal sterol-demethylase enzymes (including A. fumigatus 
Cyp51B).[17] The intrinsic fluconazole resistance of A. fumigatus appears to be a result 
of this single residue substitution. Surveillance studies of the potency of the mold-active 
triazoles against A. fumigatus clinical isolates have found isavuconazole, itraconazole, 
posaconazole, and voriconazole to all possess clinically relevant activity against A. 
fumigatus.[18] In general, the MIC of isavuconazole and itraconazole are higher, with 
MIC50 and MIC90 of 1 and 2mg/L, and 1 and 1mg/L, respectively (range 0.128-8mg/L: 
isavuconazole, 0.25-4mg/L: itraconazole). While the MIC50 and MIC90 for posaconazole 
and voriconazole are typically lower, 0.25 and 0.5mg/L for both agents (range 0.06-
1mg/L: posaconazole, 0.125-2mg/L: voriconazole).[18] 
 
The antifungal activity of the triazoles is concentration dependent. This activity 
has been shown to be best predicted by the free AUC to MIC ratio (fAUC:MIC).[19, 20] 
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Figure 1-1. Structures of the clinically relevant triazoles. 
 
 
 
 
 
 
Figure 1-2. Canonical mechanisms of triazole resistance in A. fumigatus. 
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In neutropenic murine models of pulmonary aspergillosis, the fAUC:MIC needed to 
produce a 90% reduction in fungal burden (1-log reduction) was found to be roughly 
twice that of stasis for both posaconazole and isavuconazole. This was true for triazole-
susceptible and triazole-resistant isolates.[19, 20] Additionally, the triazoles possess 
fungicidal activity at physiologically relevant concentrations against most triazole-
susceptible A. fumigatus.[21] However, this fungicidal activity is also concentration 
dependent and varies from isolate to isolate.[22] Unlike amphotericin B, the mold-active 
triazoles do not possess a clinically relevant post-antifungal effect.[23] 
 
 
Mechanisms of Triazole Resistance 
 
Considerable research has led to the identification of multiple mechanisms of 
triazole resistance among other pathogenic fungi.[24] The most predominant mechanisms 
responsible for clinically encountered triazole resistance can be grouped into three 
distinct categories; 1) mutations in the sterol-demethylase gene, 2) overexpression of the 
sterol demethylase gene, and 3) overexpression of either ATP-Binding Cassette (ABC) or 
Major Facilitator Superfamily (MFS) type drug efflux pumps.[24] While relatively less is 
understood of the mechanisms of clinical triazole resistance among A. fumigatus, much 
of what is known focuses on these three paths to triazole resistance (Figure 1-2).[9, 25, 
26] 
 
 
Mutations in the A. fumigatus Sterol-Demethylase Gene cyp51A 
 
The most commonly identified mechanism of triazole resistance among clinical 
isolates of A. fumigatus involves mutations in the sterol-demethylase gene, cyp51A.[8, 
27] A great number of these mutations have been identified among both clinical and 
environmental isolates originating from across the globe, many of which are uniquely 
found in triazole resistant isolates (Figure 1-3).[8, 28, 29] A smaller subset of these 
mutations have been shown to directly contribute to triazole resistance through genetic 
manipulations in the laboratory setting (Table 1-1).[28, 30-36] Conversely, no mutations 
which are associated with clinical triazole resistance have been found in the cyp51B 
sterol-demethylase gene at this time. 
 
 Mutations in cyp51A associated with triazole resistance are believed to result in 
amino acid substitutions which either diminish the binding affinity of triazoles with the 
sterol-demethylase enzyme, or alter the enzyme structure in a manner which favors native 
substrate conversion and thus ergosterol biosynthesis.[28, 30-36] The majority of the 
known resistance associated mutations can be grouped into distinct regions of the sterol-
demethylase enzyme. The most common and best understood of which, encode amino 
acid substitutions occurring along the ligand access channel (residues G54, P216, F219, 
and M220) or in residues which are located near the catalytic site (Y121, G138).[15] The 
ligand access channel associated residue substitutions have been shown to greatly 
decrease A. fumigatus susceptibility to both itraconazole and posaconazole, while having 
relatively less impact on voriconazole and isavuconazole susceptibilities.[30, 31, 36] It is   
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Tandem Repeat Associated 
cyp51A Mutations 
TR34/L98H 
TR46/Y121F/T289A 
TR53 
TR53/L98H 
Individual cyp51A Mutations 
Wild Type 
Residue 
Amino Acid 
Substitution 
N22 D 
G54 E, K, R, V, W 
G138 C, R, S 
P216 L 
F219 C, I, L, S 
M220 K, I, R, T, V, W 
A284 T 
I367 F 
Y431 C, S 
G432 A, C, S 
G434 C 
T440 A 
G448 S 
F495 L 
Y491 H 
 
Figure 1-3. cyp51A mutations associated with triazole resistance.  
Residues shown in bold are located along the ligand access channels, residues shown 
underlined directly interact with voriconazole. 
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Table 1-1. cyp51A mutations by residue and relative impact on triazole MIC. 
 
*data for isavuconazole not currently available, -; minimal to no impact on MIC, +; 
increase in MIC, ++; large increase in MIC 
 
 
 
 
 
 
  
 Ligand Access Channel Residues  Tandem Repeat Associated Residues 
Triazole* G54 P216 F219 M220  TR34/L98H TR46/Y121F/T289A 
Voriconazole - - - +  + ++ 
Posaconazole ++ + + +  + + 
Itraconazole ++ ++ ++ ++  ++ + 
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believed that this agent specific triazole resistance is a consequence of these amino acid 
substitutions interfering with stabilizing interactions between the long hydrophobic side 
chains present in itraconazole and posaconazole, but absent in the other two agents. 
Conversely, a mutation conferring a tyrosine to phenylalanine substitution at position 121 
(Y121F) has been shown to greatly decrease voriconazole susceptibility while having 
minimal impact on itraconazole or posaconazole.[32, 34] In x-ray crystallography 
experiments voriconazole has been observed to directly interact with tyrosine 121, though 
it is unknown if any of the other triazoles also interact with this residue.[15] 
 
In addition to mutations in the open reading frame of the cyp51A gene, sequence 
duplications forming a tandem repeat in the promoter region of cyp51A have also been 
observed.[37] These tandem repeats do not alter the Cyp51A enzyme itself, but 
significantly increase to level of cyp51A gene expression, and in turn the amount of 
Cyp51A enzyme which must be inhibited by the triazoles to block ergosterol 
biosynthesis.[26] The impact of these tandem repeat associated mutations on triazole 
resistance will be further detailed in the subsequent section. 
 
 
Overexpression of cyp51A 
 
The expression of cyp51A and cyp51B is regulated by a complex system of 
interacting transcription factors controlled by environmental conditions such as nutrient 
availability and stress. While differences are known to exist in the regulation of 
expression of the two sterol-demethylase genes, the majority of research has focused on 
cyp51A, which when overexpressed is known to contribute to clinical triazole resistance 
in A. fumigatus.[9, 26, 34, 35] It remains unknown if overexpression of cyp51B may also 
contribute to clinical resistance, but triazole-resistant clinical isolates of A. fumigatus 
have been observed to demonstrate increased expression of cyp51B.[38, 39] 
 
The positive-regulation of cyp51A expression is controlled by the sterol regulatory 
element binding protein SrbA, which binds to the promoter region of cyp51A at two 
specific binding sites as a homodimer (Figure 1-4A). One of these two binding sites is 
negatively-regulated by both the multimeric CCAAT-binding complex (CBC) 
transcription factor (comprised of HapB, HapC, and HapE) and the iron responsive basic 
region leucine zipper transcription factor, HapX. It is believed that under environmental 
conditions that favor repression of ergosterol biosynthesis and thus repression of sterol-
demethylase expression, the CBC and HapX cooperatively bind directly upstream of the 
3’ SrbA binding site and diminish the ability of SrbA to promote cyp51A expression. In 
the absence of either SrbA or the SrbA binding sites in the promoter region of cyp51A, 
cyp51A expression is essentially absent and A. fumigatus becomes hyper-susceptible to 
the triazoles.[26] 
 
Two distinct mechanisms leading to overexpression of cyp51A have been 
identified in triazole-resistant clinical isolates of A. fumigatus. By far the most prevalent 
is the formation of a tandem repeat in the promoter region of cyp51A.[8, 27] Three   
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Figure 1-4. Regulation of cyp51A expression.  
A) Regulation of cyp51A expression with SrbA homodimers under normal repression of 
CBC and HapX. B) Regulation of cyp51A expression in the presence of a tandem repeat 
mutation creating two additional SrbA binding sites not effectively repressed by the CBC 
and HapX. C) Regulation of cyp51A expression in the presence of CBC containing the 
mutant HapEP88L, which is unable to effectively repress the SrbA mediated expression of 
cyp51A. 
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versions of this tandem repeat sequence have been observed (TR34, TR46, TR53).[33, 37, 
40] Each version differs in the length of the repeated sequence (34- 53 bases), but all 
result in the formation of two additional SrbA binding sites which are not effectively 
regulated by the CBC or HapX (Figure 1-4B). Thus, cyp51A expression is increased by 
2-fold or more, and triazole MIC subsequently increase by approximately 4-fold.[26] 
Additionally, the TR34 and TR46 variations are, with only one known isolate being the 
exception, universally found in conjunction with specific mutations in the cyp51A gene 
itself, resulting in the amino acid substitutions L98H and Y121F/T289A, 
respectively.[32] Isolates possessing these mutations are often referred to as either having 
the TR34/L98H or TR46/Y121F/T289A genotype, and are most commonly observed to be 
multi- or pan-triazole-resistant. Worryingly, the prevalence of these tandem repeat 
mutations in both environmental and clinical isolates appears to be increasing around the 
world.[6, 8, 27, 37, 40] 
 
In addition to alterations of the cyp51A promoter region, a single mutation in the 
hapE gene, encoding a subunit of the CBC multimer, has been shown to directly result in 
increased cyp51A expression. This mutation was originally identified in an isogenic pair 
of clinical isolates where resistance developed on triazole therapy, and results in a P88L 
amino acid substitution in HapE.[9] CBC containing the mutant HapEP88L subunit bind 
less effectively to the promoter region of cyp51A. Thus, cyp51A expression, driven by the 
unimpeded SrbA, is increased (Figure 1-4C). Similar to what is observed with the 
tandem repeat cyp51A genotypes, this mutation in hapE leads to a 2-fold or greater 
increase in cyp51A expression and increases in MICs of all triazole that have been 
tested.[26] While screening for this hapE mutation is not commonly performed, to date 
this mechanism of triazole resistance has only been identified in the original clinical 
isolates of A. fumigatus from which it was discovered. 
 
 
Overexpression of Drug Efflux Pumps 
 
In other pathogenic fungi, efflux pump overexpression has been shown to 
contribute to clinical triazole resistance. The A. fumigatus genome is predicted to contain 
more than 300 efflux pumps, many of which have been observed to have their expression 
induced by exposure to the triazoles.[25] Furthermore, a number of these pumps have 
been observed to be constitutively overexpressed among triazole-resistant clinical 
isolates.[25, 41] However, at present relatively little is known about which of these efflux 
pumps contribute to clinical triazole resistance. In triazole-susceptible laboratory strains 
of A. fumigatus, the individual disruption of six drug efflux pump genes (abcA, abcC, 
atrF, atrI, mdrA, and mdr1) has been observed to increase triazole susceptibility.[25, 42-
46] However, only the efflux pump gene, abcA, has been demonstrated to contribute to 
triazole resistance when constitutively overexpressed in a triazole-susceptible laboratory 
strain of A. fumigatus.[45] Additionally, abcC is the only efflux pump gene which has 
been demonstrated to contribute to clinical triazole resistance. This ABC efflux pump of 
the G- subfamily is a close homolog of well characterized drug efflux pumps from other 
species of pathogenic fungi and has been observed to be overexpressed in a number of 
triazole-resistant clinical isolates of A. fumigatus. Disruption of abcC in a triazole-
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resistant clinical isolate of A. fumigatus decreased the itraconazole MIC by greater than 
4- fold, while voriconazole and posaconazole susceptibility remained unchanged. This 
clinical isolate was observed to exhibit increased constitutive expression of abcC (>5 
fold) relative to the susceptible reference strain.[25] Drug efflux pumps, have therefore 
been proven to be a mechanism by which triazole resistance is mediated in clinical 
isolates of A. fumigatus. However, the genetic determinants of drug efflux pump 
overexpression in A. fumigatus remains elusive. Recently, the zinc-cluster transcription 
factor AtrR was found to promote the expression of both cyp51A and abcC. AtrR is a 
close homolog of the Saccharomyces cerevisiae pleotropic drug response zinc-cluster 
transcription factor PDR1, and A. fumigatus strains with atrR disrupted exhibit a dramatic 
reduction in expression of both abcC and cyp51A.[46] However, the presence of 
activating mutations in atrR among triazole-resistant clinical isolates has yet to be 
identified, and its direct role in clinical triazole resistance remains unclear. 
 
 
Emerging Mechanisms of Triazole Resistance 
 
In addition to the aforementioned canonical mechanisms of triazole resistance, 
additional potential pathways to resistance in A. fumigatus are beginning to be identified. 
The most notable of which are directly linked to the ergosterol biosynthetic pathway. 
Two different studies investigating mutations acquired in laboratory strains of triazole-
susceptible A. fumigatus which develop triazole resistance upon triazole exposure have 
been successful in identifying novel resistance mechanisms. In these experiments, 
mutations in the hmg1 gene were found to confer resistance to voriconazole, itraconazole, 
and posaconazole (isavuconazole was not tested). The hmg1 gene, encodes an A. 
fumigatus homolog of 3-hydroxy-3-methyl-glutaryl (HMG) coenzyme A reductase, a key 
enzyme involved in both ergosterol and siderophore biosynthesis.[47] Additionally, a 
mutation in the cox10 gene, required for the normal biosynthesis of heme, was found to 
directly contribute to triazole resistance. Heme is utilized by a number of ergosterol 
biosynthetic genes, including cyp51A and cyp51B, to catalyze enzymatic conversion of 
sterols. The mutation in cox10 was observed to significantly reduce itraconazole 
susceptibility, yet voriconazole susceptibility was not clearly impacted.[48] While the 
roles of these mutations in clinical triazole resistance is currently unknown, these 
mutations serve to demonstrate the potential impact of non-canonical mechanisms on the 
clinical utility of the triazole antifungals and future screening for such mutations among 
clinical isolates of A. fumigatus may be merited. 
 
 
Epidemiology of Triazole Resistance 
 
Triazole resistance among A. fumigatus isolates emerged as early as the 1980’s in 
immunocompromised patients from the United States receiving itraconazole as an 
investigational agent. Subsequently, resistant isolates were recovered from patients in the 
1990’s in the Netherlands and France. However, in each of these instances, the 
identification and reporting of triazole resistance followed years after the original clinical 
cases where the isolates were cultured. 
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Today, analysis of the prevalence of triazole resistance among A. fumigatus 
remains limited by challenges in isolating Aspergillus from clinical specimens, as well as 
the additional resources and expertise required to perform antifungal susceptibility testing 
of molds.[49] However, triazole-resistant A. fumigatus are nonetheless being reported 
around the world in increasing numbers.[8, 50-53] A recent study examining the genetic 
diversity of A. fumigatus isolates observed that 6% of the 2,026 isolates obtained from 13 
countries spanning four continents, were triazole-resistant.[54] This resistance appears to 
vary dramatically by both geographic region and patient population.  
 
Both the increase in overall prevalence of triazole resistance and the variation in 
its distribution are perhaps best exemplified in epidemiology data from the Netherlands, 
where surveillance has been conducted since the first recovery of resistant clinical 
isolates. In the Netherlands, triazole resistance was originally observed to be present in 
1.8% of A. fumigatus isolates collected from 1945 to 1998. Subsequently, examination of 
resistance rates across seven Dutch university medical centers from 2007- 2009 found the 
average triazole resistance rate to have risen to 4.6%, with medical center specific rates 
ranging from 0.8% to 9.5%.[7, 51] No seasonal variation in resistance was observed and 
there was no clear geographic influence on the distribution of resistance. Importantly, the 
vast majority of triazole-resistant isolates were resistant to both itraconazole and 
voriconazole, and the case-fatality rate among patients with triazole-resistant disease was 
88%. Triazole resistance has also been observed to be more prevalent among certain 
high-risk patient populations. When resistance rates were tracked specifically among 
hematology patients at two Dutch medical centers, the prevalence of triazole resistance 
was found to be dramatically greater than that of the general population, ranging from 17 
to 30%.[55] Similar findings were also reported in a single center study of Dutch 
intensive care unit patients with invasive aspergillosis, where 26% of isolates were 
triazole-resistant.5 Overall 90-day mortality of patients with triazole-resistant disease was 
100% in this population.  
 
In the United States, triazole resistance among A. fumigatus is now being reported 
in isolates of both clinical and environmental origin.[6, 8, 56] However, only one large, 
passive, surveillance study of triazole resistance among US A. fumigatus isolates has been 
performed to date. In this study 1,026 isolates were screened and 51 (5%) were found to 
have itraconazole MIC above the EUCAST breakpoint for susceptible (CLSI has not 
published triazole breakpoints for A. fumigatus).[57] Voriconazole susceptibility was not 
reported. More recently, a study characterizing triazole-resistant isolates from the US 
performed extensive antifungal susceptibly testing on isolates collected from 2001 to 
2015. Of 26 triazole-resistant A. fumigatus clinical isolates tested, all were resistant to 
both itraconazole and posaconazole (applying EUCAST breakpoints), and only seven and 
eight, respectively, were susceptible to isavuconazole and voriconazole. Additionally, 
although the use of agricultural sterol-demethylase inhibitors is less common in the US 
than other parts of the world, a study conducted by collecting environmental samples 
from peanut fields being treated with triazole agents found 56 of 200 recovered isolates 
(28%) were triazole-resistant.[6]  
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The distribution of identifiable mechanisms contributing to triazole resistance also 
appears to vary dramatically by geographic region. In the Netherlands, as well as other 
European and Asian countries such as the United Kingdom and India, the vast majority of 
triazole-resistant isolates share at least one common resistance mechanism, comprised of 
specific combinations of mutations in the sterol-demethylase gene cyp51A in conjunction 
with the formation of tandem repeats in the cyp51A promoter region (TR34/L98H or 
TR46/Y121F/T289A genotype).[27] While many of these isolates likely possess 
additional resistance mechanisms, as suggested by the varying degrees of agent specific 
triazole resistance, the predominance of the TR34/L98H and TR46/Y121F/T289A 
genotypes among these resistant isolates cannot be overlooked. Conversely, in the United 
States only a small number of clinical isolates have been reported to possess this 
particular resistance mechanism. Of the 26 isolates in the aforementioned 
characterization of triazole-resistant A. fumigatus isolates, only two TR34/L98H and two 
TR46/Y121F/T289A genotype isolates were found. Yet, 16 isolates possessed other 
identifiable mutations in cyp51A. This discordance in prevalence of the TR34/L98H and 
TR46/Y121F/T289A genotypes has been linked to differences in the application of 
triazole related agricultural fungicides. Supporting this link, the TR34/L98H and 
TR46/Y121F/T289A genotypes are most prevalent among clinical and environmental 
samples from regions with higher utilization of these fungicides, and in vitro studies have 
demonstrated rapid acquisition of these and other cyp51A mutations upon exposure to 
agricultural triazoles. Notably, of the 56 triazole-resistant environmental samples from 
US peanut farms treated with triazoles, 21 (37.5%) were found to possess the TR34/L98H 
genotype.[6] This has led some experts to call for a reduction in the reliance on 
agricultural sterol-demethylase inhibitors in an effort to preserve the utility of the clinical 
agents.[58]  
 
While the identification and study of potential risk factors for triazole-resistant 
aspergillosis has been limited by the general paucity of susceptibility data available for 
clinical isolates, a small number of patient populations have been associated with higher 
prevalence of triazole-resistant aspergillosis. Multiple studies have observed rates of 
triazole-resistant A. fumigatus isolates from hematology-oncology patients in Europe, 
approximating and even exceeding 20%, however it is important to note that rates more 
similar to the general prevalence of resistance have been observed at other institutions. 
While prolonged use of prophylactic triazole is not uncommon in this patient population, 
these studies have also noted recovery of triazole-resistant isolates from patients with no 
prior triazole exposure, suggesting other patient factors possibly in conjunction with 
environmental acquisition of triazole-resistant isolates may be involved.[52, 55, 59, 60] 
Additionally, two epidemiologic studies examining the rates of triazole-resistant A. 
fumigatus among patients being treated in the intensive care units have also reported 
higher rates of resistance.[5, 59] Though both of these studies examined patients from 
medical centers in the Netherlands where environmental rates of triazole resistance are 
known to be high. It has been suggested that increased rates of triazole resistance among 
environmental isolates of A. fumigatus, may also increase the risk for triazole resistance 
among cases of aspergillosis.[61] This concept of environmental acquisition of resistant 
isolates is supported by a report of a patient admitted to the intensive care unit, with no 
prior history of antifungal drug exposure, suffering from proven invasive aspergillosis 
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caused by an A. fumigatus isolate harboring the TR46/Y121F/T289A genotype. 
Environmental screening of the patient’s home garden and household revealed multiple 
samples of a genetically indistinguishable and triazole-resistant A. fumigatus.[62] 
 
 
Conclusions 
 
The mold-active triazoles are essential to both prophylaxis and treatment of 
invasive aspergillosis, and few therapeutic alternatives exist. While the overall prevalence 
of triazole resistance among clinical isolates of A. fumigatus is currently observed to 
range between 1 and 10%, these estimates are limited by a relative paucity of clinical 
samples with accompanying susceptibility data. Additionally, the recent dramatic 
increase in reports of resistant isolates from both clinical and environmental sources 
worldwide is of clear concern. Mutations in cyp51A, overexpression of cyp51A, and 
efflux pump gene overexpression all are known to contribute to resistance, yet much of 
the triazole resistance among A. fumigatus still remains unexplained. Also lacking is 
clinical experience with therapeutic options for the treatment of triazole-resistant A. 
fumigatus infections, and mortality associated with these infections remains unacceptably 
high. Thus, further research is greatly needed to both better understand the emerging 
threat of triazole-resistant A. fumigatus, and to develop novel therapeutic strategies to 
combat these resistant infections. 
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CHAPTER 2.    CHALLENGING THE PARADIGM OF CLINICAL TRIAZOLE 
RESISTANCE IN ASPERGILLUS FUMIGATUS* 
 
 
Introduction 
 
Aspergillus fumigatus is the predominant pathogen isolated from patients with 
invasive aspergillosis, the most common human invasive mold infection. Invasive 
aspergillosis is responsible for more than 200,000 life-threatening infections each year, 
and afflicts up to 10% of patients with acute leukemia as well as patients receiving stem 
cell or solid organ transplantation.[1, 60, 63] Unfortunately, the mortality rates associated 
with invasive aspergillosis remain unacceptably high, often exceeding 50%, even when 
appropriately diagnosed and treated.[3-5, 60] 
 
Contributing to the poor outcomes associated with the treatment of invasive 
aspergillosis is the relative paucity of clinically available antifungal agents with 
demonstrated clinical efficacy. Of the four major classes of antifungals, only the triazoles 
and amphotericin B are recommended as monotherapy for the treatment of aspergillosis, 
with the latter relegated to second-line or salvage treatment due to significant toxicities 
and the lack of oral formulations.[10] The triazole class of antifungals therefore have 
proven essential to the treatment of invasive aspergillosis, comprising both frontline 
treatment options such as voriconazole and isavuconazole, as well as salvage options 
such as posaconazole and itraconazole.[10] These agents are generally accepted to exert 
fungicidal activity against Aspergillus through the competitive inhibition of sterol-
demethylase, encoded by the genes cyp51A (Afu4g06890) and cyp51B (Afu7g03740) in 
A. fumigatus, which results in abrogation of the synthesis of ergosterol, the major fungal 
membrane sterol.[14, 15, 64, 65] However, the treatment of invasive aspergillosis has 
recently been further complicated by the global emergence of triazole-resistant disease. 
Over the past decade, triazole resistance among clinical isolates of A. fumigatus has been 
increasingly reported on six continents, with resistance rates exceeding 20% now being 
reported in some studies.[6-8, 30]  
 
Considerable research has led to the identification of three distinct molecular 
pathways to clinical triazole resistance in A. fumigatus. These three paths largely mirror 
the established mechanisms of resistance previously identified in other pathogenic fungi 
such as Candida albicans; 1) mutations in the sterol-demethylase gene cyp51A, 2) 
overexpression of the sterol-demethylase gene cyp51A, and 3) overexpression of the 
efflux pump-encoding gene abcC [9, 25, 26, 28, 31, 32, 34-36, 66]. However, it remains 
unknown to what extent these mechanisms explain the degree of triazole-resistance 
observed among clinical isolates of A. fumigatus, and resistant clinical isolates exhibiting  
 
----------------- 
* Modified from final submission with permission. Rybak JM, Ge W, Wiederhold NP, 
Parker JE, Kelly SL, Rogers PD and Fortwendel JR. Mutations in hmg1, challenging the 
paradigm of clinical triazole resistance in Aspergillus fumigatus. MBio. 2019 Apr 
2;10(2). pii: e00437-19. doi: 10.1128/mBio.00437-19.  
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none of these three mechanisms have been repeatedly identified.[25] Thus, the molecular 
mechanisms underpinning much of the clinical resistance to this essential class of anti-
Aspergillus agents remains unexplained, limiting the discovery of therapeutic strategies 
to overcome triazole-resistant aspergillosis.  
 
In this work, we perform a comprehensive characterization of the direct 
contributions of previously identified mechanisms of triazole resistance in a large 
collection of triazole-resistant clinical isolates of A. fumigatus. We correct cyp51A 
mutations in 10 different triazole-resistant clinical isolates using a novel Cas9-mediated 
transformation system to delineate the direct impact these mutations have on clinical 
triazole susceptibility, and we assess the potential impact of overexpression of cyp51A, 
cyp51B, and abcC on triazole susceptibility in a collection of 21 triazole-resistant clinical 
isolates. We subsequently demonstrate that these mechanisms alone fail to explain the 
resistance observed in this collection, suggesting the presence of additional mechanisms 
of clinical triazole resistance yet to be identified.  
 
 
Materials and Methods 
 
 
Isolates, Media, and Growth Conditions Used 
 
Twenty-one previously characterized multi-triazole-resistant clinical isolates of A. 
fumigatus, and five triazole-susceptible control clinical isolates of A. fumigatus, 
originating from the United States were obtained from the Fungus Testing Laboratory at 
the University of Texas in San Antonio. The laboratory strains akuBKU80 and Af293 were 
obtained from the Fungal Genetics Stock Center. All strains and clinical isolates used in 
this study were maintained on glucose minimal media (GMM) agar at 37°C. 
Transformants were selected for using sorbitol (1.2M) supplemented GMM agar (SMM) 
containing 150mg/L of hygromycin. All conidia were harvested in sterile water from 
three-day-old growth plates and conidia were enumerated visually using a 
hemocytometer. 
 
 
Whole Genome Sequencing 
 
For each isolate, genomic DNA was extracted using the Qiagen DNeasy Plant 
Mini Kit as previously described.[67] DNA concentrations were quantified using both the 
Qubit Fluorometer and Nanodrop spectrophotometer using the manufacturers’ protocols. 
Whole genome libraries were prepared and sequenced at the University of Tennessee 
Health Science Center Molecular Resource Center. Bioinformatics services were 
provided by code4DNA (www.code4DNA.com). Sequence reads for each sample were 
aligned using the STAR sequence alignment tool (v2.5.0b) to the A. fumigatus reference 
sequence (version A_fumigatus_Af293_version_s03-m05-r05) which was downloaded 
from http://aspgd.org/. Duplicate alignments were marked using Picard (v1.119) and 
variants were called using Freebayes (v1.1.0) using the haploid population-based model. 
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The Freebayes output vcf file was split into individual sample vcf files using bcftools 
(v1.3) and variants for each sample were annotated with snpEff (v4.2) using the A. 
fumigatus reference sequence annotations. 
 
 
Construction of Promoter Replacement Repair Templates and Cas9-RNP for 
cyp51A, cyp51B, and abcC 
 
 The plasmid pJMR2 was constructed by cloning the proximal 1kb of the promoter 
sequence from the A. fumigatus heat shock protein-encoding gene, hspA, into the plasmid 
pCR-HygR.[67] Then promoter replacement transformation repair templates for cyp51A, 
cyp51B, and abcC were created by PCR using primers (Table 2-1) which amplified both 
the hygromycin resistance cassette and the hspA promoter from the plasmid pJMR2, 
while also introducing approximately 40 bases of homology targeting sequences 
immediately upstream and downstream of the start codon for the respective gene of 
interest. PCR products were subsequently purified using the Gene Clean II Kit (MP 
Biomedicals). Cas9-RNP complexes targeting sequences immediately upstream of the 
open reading frame of each gene of interest were assembled as previously described.[67] 
 
 
Assessment cyp51A, cyp51B, and abcC Expression by RTqPCR 
 
For assessment of expression in clinical isolates, conidia from each isolate were 
allowed to germinate overnight in Aspergillus minimal media incubated at 37°C on an 
orbital shaker at 250 RPM. For assessment of expression in constitutive overexpression 
strains constructed in the akuBKU80 background, conidia from each isolate were allowed 
to germinate overnight in Aspergillus minimal media incubated at 37°C on an orbital 
shaker at 250 RPM, then transferred to fresh Aspergillus minimal media either with 
voriconazole 0.125mg/L (treated) or without voriconazole (untreated) for an additional 6 
hours at 37°C on an orbital shaker at 250 RPM. Then RNA was extracted from mature 
hyphae following liquid nitrogen crush as previously described.[68] The RevertAid RT 
kit (Thermo Scientific) was utilized to synthesize cDNA. PCR master mix and SYBR 
were utilized to amplify A. fumigatus cyp51A, cyp51B, and abcC from cDNA by PCR per 
the manufacturer’s instructions. Table 2-1 lists the gene specific primers used for PCR. 
Conditions used for PCR were as follows: AmpliTaq Gold activation at 95°C for 10 
minutes, 40 cycles of denaturation at 95°C for 15 seconds and annealing/ extension at 
60°C. The dissociation curve and threshold cycle (CT) was determined using the CFX96 
Real Time PCR system (Bio-Rad). Changes in gene expression among isolates were then 
calculated using the 2-ΔΔCT method. All experiments were performed in triplicate from 
biological triplicates. As previously described, ΔCT values were used to calculate the 
standard error.[68] Statistical analysis was performed using unpaired, two-tailed, students 
t-test in Prism 8 for Mac OS by GraphPad Software Inc. with significance set at 0.05 and 
degrees of freedom equal to 10. 
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Table 2-1. Oligonucleotides used for cyp51A, cyp51B, and abcC experiments. 
 
Oligo Type   Gene        Primer Name Sequence (5'- 3') 
PCR Primers 
 cyp51A cyp51A KI F CRISPR GAATACTGGGCAGCGGGCTGGAGATACT
ATGGCTTTCATATGTTGCTCAGCGTCAGC
ATTCTGAAACACG 
 cyp51A cyp51A KI R CRISPR CCAGTAAGGTCTGAATAAGGGTTCAATA
CAGTCATTTATTAGGCCCTCGATTCGAGC
TCCCAAATCTGTCCAG 
 cyp51A cyp51A OE hspA F CATTTCCCTCATCACTGCAACTCTAATCC
TCGGGCTCACCCAGCTTGCATGCCTGCA
GG 
 cyp51A cyp51A OE hspA R ACGGCCATGTAGGCCGTAAGCCATAGCA
TCGGCACCATGCTTGGTACCTGTGAAGA
AGTG 
 cyp51B cyp51B OE hspA F CTACCTTTATTCCCTGCGACAGTAACTCG
GTTGATCGATTTGAGCTTGCATGCCTGCA
GG 
 cyp51C cyp51B OE hspA R TTGCAGATGCCGTCGAGAATGAACGCGA
TGAGACCCATGCTTGGTACCTGTGAAGA
AGTG 
 abcC abcC OE hspA F GTTCGACTGTTTATGTGTATACCTATTGT
GACGCAACCACTCAGCTTGCATGCCTGC
AGG 
 abcC abcC OE hspA R GGGTTGATGTTAGGATTTATCGTCCCTAG
AAGAGACATGCTTGGTACCTGTGAAGAA
GTG 
 
 
hphR hphR screen R CAAATCGCCCGCAGAAGCG 
crRNA Guide Sequences 
 cyp51A cyp51A 5’ crRNA GGCTTTCATATGTTGCTCAG 
 cyp51A cyp51A 3’ crRNA TTCAAAGGATTTGGTGTGAT 
 cyp51A cyp51B 5’ OE crRNA CTCCCTGTGTCTCCTCGAAA 
 cyp51B cyp51B 5’ OE crRNA TATTCCCTGCGACAGTAACT 
 
 
abcC abcC 5’ OE crRNA GACTGAGTGTCTCACTCAAT 
RTqPCR Primers 
 cyp51A cyp51A RT F e1 CTTCTTTGCGTGCAGAGA 
 cyp51A cyp51A RT R e2 GGGGTCGTCAATGGACTA 
 cyp51B cyp51B RT F e1 CTTTTTCGACTGCCGCGC 
 cyp51B cyp51B RT R e2 AGGCGTAGTGAGTGGAGA 
 abcC abcC RT F e1 CCTGGAGAAGGTCTCAATGTCG 
 abcC abcC RT R e2 GGCCAGACGTAGGCTCATCC 
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Construction of Allele Replacement Repair Templates and Cas9-RNP for the 
cyp51A Locus 
 
The plasmid pCyp51A-HygR was created by cloning the proximal 1.5kb of 
promoter sequence and open reading frame of the wild-type cyp51A allele from the 
genomic reference strain Af293, upstream of the hygromycin resistance cassette in the 
plasmid pCR-HygR, and then cloning the proximal 1.5kb of the wild-type cyp51A 
terminator downstream of the hygromycin resistance cassette. Then, the cyp51AWT 
transformation repair template was created by PCR using primers which amplified the 
wild-type cyp51A allele (including 500 bases of promoter sequence), the hygromycin 
resistance cassette, and 500 bases of the cyp51A terminator. Cas9-RNP complexes 
targeting sequences immediately upstream and approximately 500 bases downstream of 
the open reading frame of cyp51A were assembled as previously described.[67] Target 
specific guide sequences are listed in Table 2-1. 
 
 
Aspergillus Protoplast Transformations 
 
Transformation of A. fumigatus protoplasts were performed as previously 
described with minor modifications.[67] Approximately 2μg of each portion applicable 
transformation repair templates were then mixed with 200 μL of protoplasts, 26.5 μL of 
Cas9-RNP complexes, and 25 μL of polyethylene glycol (PEG)-CaCl2 buffer (60% 
[wt/vol] PEG 3350, 50 mM CaCl2·H2O, 450 mM Tris-HCl, pH 7.5) as previously 
described. Following an incubation on ice for approximately one hour, 1.25mL PEG-
CaCl2 was added and the mixture incubated for an additional 20 minutes at room 
temperature. The mixture was then diluted to a total volume of 3 mL with STC buffer 
(1.2 M sorbitol, 7.55 mM CaCl2·H2O, 10 mM Tris-HCl, pH 7.5) and plated on SMM 
agar plates. Plates were then incubated overnight prior to being overlaid with SMM top 
agar (GMM supplemented with 1.2 M sorbitol and 0.7% [wt/vol] agar) supplemented 
with hygromycin (final concentration of 150 g/ml), and the plates were incubated at 37°C 
for 3 days. Transformants were isolated to separate plates containing selective agar, 
genomic DNA extracted, and successful CRISPR/Cas9 editing confirmed by PCR 
screens using gene-specific primers and Sanger sequencing. 
 
 
Clinical Antifungal Susceptibility Testing 
 
Susceptibilities for amphotericin B, voriconazole, isavuconazole, itraconazole, 
and posaconazole were determined for all isolates in accordance with CLSI M38-A2 
methodology utilizing broth microdilution in RPMI[69]. Each antifungal was obtained 
from the appropriate manufacturer. All agents were suspended in dimethyl sulfoxide 
(DMSO) for preparation of stock solutions. 
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Data Availability 
 
Whole genome sequencing data files for the 26 Aspergillus fumigatus isolates 
have been deposited to NCBI SRA under the accession number PRJNA491253. 
 
 
Results 
 
 
Mutations in Sterol-Demethylase Alone Poorly Explain Clinical Triazole Resistance 
 
Mutations in the sterol-demethylase gene cyp51A are the most frequently 
identified mechanism of triazole resistance in A. fumigatus.[5, 8, 70] We sought to 
delineate the proportion of triazole resistance observed in individual clinical isolates 
explained by this mechanism. To accomplish this, a collection of 26 clinical isolates of A. 
fumigatus originating from the United States were obtained from the Fungus Testing 
Laboratory at the University of Texas Health Science Center at San Antonio, including 
21 multi-triazole-resistant isolates with previously reported clinical origins and 
characterized cyp51A genotypes, and 5 triazole-susceptible control isolates.[8] High 
quality genomic DNA was extracted from each of the 26 isolates, whole genome 
sequencing was performed targeting a read depth of approximately 100 reads per base 
aligned to the Af293 A. fumigatus reference genome assembly, and a total of 48,552 
SNPs, insertion or deletions (indels) unique to triazole-resistant isolates were identified 
within 8,669 genes with annotations available. Of the 21 triazole-resistant isolates in this 
collection, 16 were identified as possessing peptide sequence altering cyp51A mutations 
unique to resistant isolates. Conversely, no unique cyp51B mutations were identified. We 
selected 10 of these 16 isolates with cyp51A mutations, which also exhibited resistance to 
all clinically available triazole agents, for correction of the cyp51A sequence to that of the 
wild-type consensus sequence. These isolates included examples of previously 
characterized cyp51A mutations (TR34/L98H, TR46/Y121F/T289A, G448S), mutations at 
residues where alternative mutations have previously been characterized (G138C and 
F219S), and mutations never before characterized to our knowledge (M263I and I367F) 
(Table 2-2).[28, 34, 35, 48, 71] 
 
In order to test the direct contribution of these mutations to clinical triazole 
resistance in these isolates, the wild-type cyp51A promoter region and open reading 
frame from the triazole-susceptible reference strain Af293 was first cloned upstream of 
the hygromycin resistance cassette in plasmid pCR-HygR.[67] 1500 bases of the cyp51A 
terminator was then cloned downstream of the hygromycin resistance cassette, yielding 
the plasmid pCyp51A-HygR. Then, the cyp51AWT transformation repair template was 
created by PCR using primers which amplified the wild-type cyp51A allele (including 
500 bases of promoter sequence), the hygromycin resistance cassette, and 500 bases of 
the cyp51A terminator. Importantly, this repair template extends approximately 200 bases 
upstream of the promoter region where characterized regulatory elements and tandem 
repeat sequences have been identified.[26] Protoplasts of each of the 10 triazole-resistant 
clinical isolates, as well as the well-characterized triazole-susceptible laboratory strain  
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Table 2-2. Triazole MIC of clinical isolates and derivative cyp51AWT strains. 
 
Parent Clinical Isolate or  Triazole MIC (mg/L) 
Derivative cyp51AWT Strain cyp51A Genotype Voriconazole Itraconazole Posaconazole 
DI15-117  F219S 2 ≥32 2 
     DI15-117 cyp51AWT WT 4 ≥32 4 
     
DI15-100  M263I 8 ≥32 1 
     DI15-100 cyp51AWT WT 8 ≥32 0.5 
     
DI15-116 TR34/L98H 8 ≥32 1 
     DI15-116 cyp51AWT WT 1 0.25 0.125 
     
DI15-102 TR34/L98H 8 ≥32 2 
     DI15-102 cyp51AWT WT 4 ≥32 0.5 
     
DI15-108 G138C 4 ≥32 1 
     DI15-108 cyp51AWT WT 4 ≥32 0.125 
     
DI15-95 M263I 16 ≥32 2 
     DI15-95 cyp51AWT WT 16 ≥32 1 
     
DI15-98 I367F 16 16 2 
     DI15-98 cyp51AWT WT 16 ≥32 1 
     
DI15-96 TR46/Y121F/T289A ≥32 4 1 
     DI15-96 cyp51AWT WT ≥32 0.5 0.25 
     
DI15-106 TR46/Y121F/T289A ≥32 4 1 
     DI15-106 cyp51AWT WT 8 2 0.5 
     
DI15-120 G448S ≥32 ≥32 1 
     DI15-120 cyp51AWT WT ≥32 ≥32 1 
 
MIC shown in bold are greater than epidemiologic cutoff values as published by the 
Clinical Laboratory and Standards Institute (1mg/L for voriconazole and itraconazole; 
0.25mg/L for posaconazole). WT: cyp51A sequence matches the Af293 wild-type 
consensus sequence. 
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akuBKU80 (CEA17 ΔakuBKU80) which has a wild-type cyp51A allele, were then 
transformed with Cas9-ribonucleoprotein (RNP) complexes, consisting of Cas9 protein 
and crRNA-trRNA duplexes targeting sequences immediately upstream and downstream 
of the cyp51A locus. The resulting transformants were selected on Aspergillus minimal 
media containing hygromycin as previously described.[67, 72] Integration of the repair 
template at the native cyp51A locus was confirmed by PCR, and acquisition of the 
cyp51AWT sequence was verified by Sanger sequencing. 
 
Clinical susceptibility testing was performed for each of the 10 triazole-resistant 
clinical isolates and the corresponding cyp51AWT derivative strains for voriconazole, 
itraconazole, and posaconazole according to the Clinical Laboratory Standards Institute 
M38-A2 standards (Table 1).[69] All of the resistant clinical isolates exhibited triazole 
minimum inhibitory concentrations (MIC) consistent with those previously reported for 
these isolates under clinical susceptibility testing conditions, and all MIC for each agent 
tested were above epidemiologic cut-off values previously reported by CLSI (1mg/L for 
voriconazole and itraconazole, 0.25mg/L for posaconazole).[8, 73] Among the cyp51AWT 
strains, only one strain (DI15-116 cyp51AWT) was observed to have full restoration of 
wild-type triazole susceptibility, and two strains (DI15-96 cyp51AWT and DI15-108 
cyp51AWT) were observed to have restoration of wild-type susceptibility to at least one 
triazole. Additionally, two strains (DI15-102 cyp51AWT and DI15-106 cyp51AWT) were 
observed to have at least one triazole MIC decrease by more than one dilution. Five of 
the 10 cyp51AWT derivative strains exhibited no change in susceptibility to any triazole 
agent tested. Importantly, replacement of the native wildtype cyp51A allele with the 
cyp51AWT cassette in the akuBKU80 background had no effect on triazole MIC. Taken 
together, these data demonstrate that while mutations in cyp51A are common among 
triazole-resistant clinical isolates of A. fumigatus, and a number of these mutations have 
been demonstrated to increase triazole MIC when introduced into a triazole susceptible 
background, mutations in cyp51A alone poorly explain the high level of triazole 
resistance observed in this collection of clinical isolates. 
 
 
Analysis of the Expression of the Sterol-Demethylases Genes cyp51A and cyp51B 
Among Triazole-Resistant Clinical Isolates. 
 
Triazole-resistant clinical isolates of A. fumigatus exhibiting overexpression of 
cyp51A and cyp51B, relative to susceptible comparator isolates, have previously been 
reported.[25, 39] Additionally, both the formation of tandem repeats (TR34, TR46, and 
TR53) in the promoter region of cyp51A and a mutation (encoding the amino acid 
substitution P88L) in hapE, a CCAAT-binding complex protein-encoding gene which 
participates in the negative regulation cyp51A expression, have been shown to increase 
both cyp51A expression and triazole MICs.[9, 26, 34] Following the observation that 
mutations in cyp51A alone do not explain the degree of triazole resistance observed in 
this collection of clinical isolates, we sought to evaluate the potential contributions of 
sterol-demethylase gene overexpression to clinical triazole resistance. To accomplish 
this, each of the 26 clinical isolates in our collection were grown overnight at 37 °C in 
Aspergillus minimal media in biological triplicate, and RNA was extracted from mature 
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hyphae following liquid nitrogen crush as previously described.[68] Reverse transcription 
quantitative-PCR (RTqPCR) was then utilized to quantify the relative expression of both 
cyp51A and cyp51B in each of the 21 triazole-resistant clinical isolates as compared to the 
expression level observed among the 5 triazole-susceptible control isolates.  
 
The expression of cyp51A and cyp51B in all clinical isolates was compared to the 
triazole-susceptible isolate DI16-6 (voriconazole MIC 0.5 mg/L). Among triazole-
susceptible control isolates, the expression of cyp51A ranged from 0.5 to 1.6-fold that of 
isolate DI16-6 (Figure 2-1A), with isolates DI16-5, DI-16-7, and DI16-9 exhibiting 
statistically significant lower expression of cyp51A. While the expression of cyp51A 
among triazole-resistant clinical isolates ranged from 0.7 to 3.5 –fold that of the 
susceptible comparator isolate. Twelve of the 21 triazole-resistant isolates were observed 
to have cyp51A expression that exceeded the highest expression level observed among 
triazole-susceptible isolates. Of these 12 isolates, 8 were found to have cyp51A 
expression levels statistically greater than the susceptible comparator isolate. This 
included 2 isolates (DI15-102 and DI15-116) which possess the TR34/L98H cyp51A 
mutation, 2 isolates (DI15-96 and DI15-106) which possess the TR46/Y121F/T289A 
cyp51A mutation, and one isolate (DI15-105) which possesses the previously 
characterized P88L-encoding mutation in hapE. However, no previously characterized 
mutations known to contribute to cyp51A overexpression, were identified in the 
remaining 3 isolates. The expression of cyp51B among the triazole-susceptible control 
isolates ranged from 0.7 to 1.3-fold that of isolate DI16-6 (Figure 2-1B), with isolate 
DI16-8 exhibiting statistically greater expression of cyp51B (1.3 fold). The expression of 
cyp51B among triazole-resistant clinical isolates ranged from 0.7 to 2.1-fold that of the 
susceptible comparator isolate, with 4 isolates (DI15-95, DI15-97, DI15-102 and DI15-
108) exhibiting expression of cyp51B exceeding that of the highest expression level 
observed among triazole-susceptible isolates, 3 of which (DI15-95, DI15-102 and DI15-
108) were statistically significant. 
 
 
Constitutive Overexpression of cyp51B Decreases Triazole Susceptibility 
 
Overexpression of cyp51A has previously been shown to contribute to triazole 
resistance, but it remains unknown if overexpression of the paralogous gene, cyp51B, has 
a similar effect on triazole susceptibility. We sought to employ a novel Cas9-RNP 
mediated promoter replacement system to delineate the direct impact of constitutive 
overexpression of cyp51B on triazole MIC. To accomplish this, the previously 
characterized, strong, constitutive promoter from the heat shock protein encoding gene, 
hspA (Afu1g07440), was cloned upstream of the hygromycin resistance cassette in the 
plasmid pCR-HygR.[74] A transformation repair template for the cyp51B promoter 
replacement was then constructed by amplifying the hspA promoter and hygromycin 
resistance cassette from the resulting plasmid (pJMR2) with primers that introduced 
approximately 50 bases of homology for the 3’ end of the native promoter region and the 
5’ end of the cyp51B open reading frame. Protoplasts of the well-characterized triazole-  
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Figure 2-1. Relative expression of cyp51A and cyp51B among triazole-resistant 
clinical isolates. 
A) Expression of cyp51A in clinical isolates relative to triazole-susceptible isolate DI16-
6, identified mutations known to contribute to cyp51A overexpression are shown on the 
corresponding bar B) expression of cyp51B in clinical isolates relative to triazole-
susceptible isolate DI16-6; Triazole-susceptible isolates shown as open bars, triazole-
resistant isolates shown as filled bars. Triazole-resistant isolates shown in order of 
escalating voriconazole MIC from left to right. Horizontal dotted lines denote highest and 
lowest expression level observed among the 5 triazole-susceptible isolates. Comparisons 
with the susceptible control isolate DI16-6 with statistically significant (p<0.05) results 
are noted with an Asterix. 
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susceptible laboratory strain akuBKU80 were then transformed with Cas9-RNP complexes, 
consisting of Cas9 protein and crRNA-trRNA duplexes targeting sequences immediately 
upstream of the cyp51B start codon, yielding the strain akuBKU80_PhspAcyp51B (Figure   
2-2).[75] As a comparator, the same methodology was employed to create the 
constitutive cyp51A overexpressing strain, akuBKU80_PhspAcyp51A. 
 
 The relative expression of both cyp51A and cyp51B in the strains 
akuBKU80_PhspAcyp51A and akuB
KU80_PhspAcyp51B was then compared to the parental 
akuBKU80 strain under both normal growth conditions and following voriconazole 
treatment. Conidia from each strain were growth in Aspergillus minimal media at 37 °C 
until germination, and then were transferred to fresh Aspergillus minimal media 
containing either no voriconazole, or 0.125mg/L of voriconazole (half of the MIC of the 
parental akuBKU80 strain) for an additional 6 hours at 37 °C. RNA was extracted from 
each sample as previously described and RTqPCR was performed. The expression of 
cyp51B in akuBKU80 was 2-fold higher after treatment with voriconazole than in untreated 
conditions (Figure 2-3A). Expression of cyp51B in the akuBKU80_PhspAcyp51B strain was 
35.9-fold higher under untreated conditions, and 36.9-fold higher following voriconazole 
exposure, as compared to the expression measured in the parental akuBKU80 under 
untreated conditions. This increased expression was statistically greater than in the 
parental strain under both treated and untreated conditions. The expression of cyp51B in 
the akuBKU80_PhspAcyp51A strain approximated that of akuB
KU80 under both untreated and 
voriconazole-treated conditions. The expression of cyp51A in akuBKU80 was 4.1-fold 
higher following treatment with voriconazole as compared to untreated conditions. 
Expression of cyp51A in the akuBKU80_PhspAcyp51A strain was 14.1-fold higher under 
untreated conditions, and 18.5-fold higher following voriconazole exposure, as compared 
to the expression measured in the parental akuBKU80 under untreated conditions. This 
increased expression was statistically greater than in the parental strain under both treated 
and untreated conditions. The expression of cyp51A in the akuBKU80_PhspAcyp51B strain 
was similar to that of akuBKU80 under both untreated and voriconazole-treated conditions.  
 
Upon confirmation of the constitutive overexpression of cyp51A and cyp51B in 
the akuBKU80_PhspAcyp51A and akuB
KU80_PhspAcyp51B strains, respectively, voriconazole 
MIC were performed in triplicate according to CLSI M38-A2 standards.[69] The parental 
akuBKU80 strain exhibited a voriconazole MIC of 0.25mg/L. The akuBKU80_PhspAcyp51A 
strain was observed to have a 2-fold increase in voriconazole MIC (0.5mg/L), which is 
similar to the decrease in susceptibility previously reported when expression of this gene 
is increased as a result of either the formation of tandem repeats in the cyp51A promoter 
or a mutation in hapE (Figure 2-3B)[9, 26, 34, 35]. Interestingly, the voriconazole MIC 
of the akuBKU80_PhspAcyp51B strain was 1mg/L, 4-fold higher than the parental isolate. 
Taken together, these results demonstrate that overexpression of either sterol-
demethylase gene can decrease triazole susceptibility. However, even when the 
expression of either of these genes increase by as much as 36.9-fold, MIC did not exceed 
the epidemiological cutoff-value for voriconazole reported by CLSI (1mg/L).[73] 
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Figure 2-2. Schematic of Cas9-RNP mediated promoter replacement system. 
Constitutive overexpression repair templates were amplified from pJMR2 using primers 
incorporating microhomology targeting genes of interest (GOI), then mixed with Cas9-
RNP targeting immediately upstream of the start codon of the GOI, and protoplasts 
created from the strain akuBKU80. 
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Figure 2-3. Relative expression of cyp51A and cyp51B, and voriconazole MIC in 
promoter replacement strains akuBKU80_PhspAcyp51A and akuBKU80_PhspAcyp51B. 
The expression of A) cyp51A and cyp51B in akuBKU80, akuBKU80_PhspAcyp51A, and 
akuBKU80_PhspAcyp51B was determined by RTqPCR following growth in Aspergillus 
minimal media at 37 °C both with voriconazole (0.125mg/L) treatment for 6 hours, and 
without voriconazole treatment. The expression level for each sample is shown relative to 
that of the respective gene in akuBKU80 without voriconazole treatment. B) Voriconazole 
MIC for akuBKU80, akuBKU80_PhspAcyp51A, and akuB
KU80_PhspAcyp51B. Comparisons with 
statistically significant (p<0.05) results are noted with an Asterix, while those that are not 
are noted with “ns”. 
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Analysis of the Expression of the Efflux Pump-Encoding Gene abcC Among 
Triazole-Resistant Clinical Isolates 
 
In addition to sterol-demethylase-mediated mechanisms of triazole resistance, 
increased constitutive expression of the ATP-binding cassette efflux pump encoding 
gene, abcC (Afu1g14330; also known as abcB, cdr1B, and abcG1), has been associated 
with triazole resistance in A. fumigatus.[25, 48, 66] Furthermore, deletion of abcC in both 
triazole-susceptible laboratory strains of A. fumigatus, as well as a triazole-resistant 
clinical isolate, has been shown to increase triazole susceptibility.[25, 48, 66] As cyp51A 
and cyp51B-mediated mechanisms alone do not adequately explain the high level of 
triazole-resistance in this collection of clinical isolates, we sought to characterized the 
expression of abcC and its potential impact on triazole susceptibility. To accomplish this, 
each of the 26 clinical isolates in our collection were grown overnight at 37 °C in 
Aspergillus minimal media in biological triplicate, and RNA was extracted as previously 
described. RTqPCR was then utilized to quantify the relative expression of abcC in each 
of the 21 triazole-resistant clinical isolates as compared to the expression level observed 
among the 5 triazole-susceptible control isolates.  
 
The expression of abcC in all clinical isolates was compared to the triazole-
susceptible isolate DI16-6. Among triazole-susceptible control isolates, the expression of 
abcC ranged from 0.7 to 2-fold that of isolate DI16-6 (Figure 2-4A), with both isolates 
DI16-5 and DI16-8 exhibiting statically greater abcC expression (1.3 and 2.0-fold 
respectively) than DI16-6. The expression of abcC among triazole-resistant clinical 
isolates ranged from 1.2 to 33.2-fold that of the susceptible comparator isolate. Nineteen 
of the 21 triazole-resistant isolates were observed to have abcC expression that was 
statistically greater than the expression observed in the susceptible control isolate DI16-6, 
14 of which exhibited abcC expression which also exceeded the highest expression level 
observed among triazole-susceptible isolates (2-fold). While the majority of these 14 
isolates exhibited modestly elevated abcC expression (2.4 to 4.1-fold that of the 
comparator susceptible isolate) isolates DI15-110, DI15-120, and DI15-106 exhibited 
markedly higher levels of abcC expression (6.5, 10.4, and 33.2-fold, respectively). 
Notably, the pan-triazole-resistant isolate DI15-110, which exhibited the highest level of 
abcC expression, possesses no mutations in cyp51A and did not exhibit increased 
constitutive expression of either sterol-demethylase gene. 
 
As previous studies associating increased triazole resistance to abcC have entirely 
relied upon deletion of the abcC gene among either clinical or laboratory isolates of A. 
fumigatus, we next sought to utilize our Cas9-RNP mediated promoter replacement 
system to delineate the direct impact of constitutive overexpression of abcC on triazole 
MIC. To accomplish this, protoplasts of the triazole-susceptible laboratory strain 
akuBKU80 were transformed with Cas9-ribonucleoprotein (RNP) complexes, consisting of 
Cas9 protein and crRNA-trRNA duplexes targeting sequences immediately upstream of 
the abcC start codon, as well as the PhspAabcC transformation repair template which 
contains both the hspA promoter and hygromycin resistance cassette flanked by 50-bases 
of micro-homology targeting the abcC locus, yielding the strain akuBKU80_PhspAabcC. 
Subsequently, the relative expression of abcC in both akuBKU80PhspAabcC and the  
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Figure 2-4. Relative expression of abcC in triazole-resistant clinical isolates and 
the constitutive overexpression strain akuBKU80_PhspAabcC. 
Triazole-susceptible isolates shown as open bars, triazole-resistant isolates shown as 
filled bars. Triazole resistant isolates shown in order of escalating voriconazole MIC 
from left to right. Horizontal dotted lines denote highest and lowest expression level 
observed among the 5 triazole-susceptible isolates. a) expression of abcC relative to 
triazole-susceptible isolate DI16-6. b) The expression of abcC in strains akuBKU80 and 
akuBKU80_PhspAabcC was determined by RTqPCR following growth in Aspergillus 
minimal media at 37 °C both with voriconazole (0.125mg/L) treatment for 6 hours, and 
without voriconazole treatment. The expression level for each sample is shown relative to 
that of the respective gene in akuBKU80 without voriconazole treatment. Comparisons 
with statistically significant (p<0.05) results are noted with an Asterix, while those that 
are not are noted with “ns”. 
  
 30 
parental strain akuBKU80 was assessed by RTqPCR following growth in Aspergillus 
minimal media at 37 °C both with voriconazole treatment (0.125mg/L) for 6 hours and 
without. 
 
 In the parental akuBKU80 strain, abcC expression was significantly (9.7-fold) 
higher following voriconazole treatment than was observed without voriconazole 
treatment (Figure 2-4B). By comparison, the akuBKU80_PhspAabcC strain exhibited 7.8-
fold and 10.4-fold abcC expression, under untreated and voriconazole-treated conditions, 
respectively, as compared to the expression of abcC measured in the parental akuBKU80 
under untreated conditions. abcC expression was not found to be significantly different 
between akuBKU80_PhspAabcC and the parental strain when both had been treated with 
voriconazole for 6 hours. Surprisingly, even with an approximate 10-fold increase in the 
constitutive expression of abcC, the akuBKU80_PhspAabcC strain did not demonstrate any 
change in voriconazole susceptibility relative to the parental akuBKU80 strain (MIC 
0.25mg/L). 
 
 
Conclusions 
 
 In this work, we performed a comprehensive characterization of the direct 
contributions of previously identified mechanisms of triazole resistance in a collection of 
triazole-resistant clinical isolates of A. fumigatus. We observed that correction of cyp51A 
mutations in 10 pan-triazole-resistant clinical isolates only restored wild-type 
susceptibility, to even a single triazole agent, in 3 isolates. We then demonstrated that 
while constitutive overexpression of cyp51A, and to a lesser extent cyp51B, was common 
among isolates in this collection, increasing expression of either sterol-demethylase gene 
by as much as 18 to 36-fold in the triazole-susceptible akuBKU80 background, had a 
limited effect on triazole MIC. Analogously, we then observed that while the expression 
of the ABC-type efflux pump-encoding gene abcC was higher among 14 of the triazole-
resistant isolates in this collection, constitutive overexpression of this gene in the 
akuBKU80 background did not have any effect on voriconazole MIC.  
 
 Taken together, these data serve to demonstrate that while the canonical 
mechanisms of triazole resistance, even when considered collectively, do not adequately 
explain the triazole resistance observed in this collection of A. fumigatus clinical isolates, 
and additional mechanisms yet to be identified are likely present in this collection. 
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CHAPTER 3.    THE ASPERGILLUS FUMIGATUS EFFLUX PUMP-ENCODING 
GENES ABCA AND ATRI ARE NOT SIGNIFICANT CONTRIBUTORS TO 
CLINICAL TRIAZOLE RESISTANCE* 
 
 
Introduction 
 
 Aspergillus fumigatus is the principal etiological agent of invasive aspergillosis, a 
devastating disease state responsible for more than 200,000 life-threatening infections 
each year, and predominantly afflicting the expanding population of 
immunocompromised patients.[1, 2] Unfortunately, even among patients appropriately 
diagnosed and receiving the best available treatment, clinical outcomes associated with 
invasive aspergillosis remain poor with mortality rates ranging from 30-90%.[3-5, 60]  
 
Potentially contributing to these poor outcomes, is the paucity of therapeutic 
options for the treatment of invasive aspergillosis. Of the relatively limited 
armamentarium of clinically available antifungals, only the triazoles, the echinocandins, 
and the polyene amphotericin B, are commonly utilized for the treatment of invasive 
aspergillosis. However, amphotericin B is most often recommended as salvage or second-
line therapy, because of both limitations in available formulations and a less favorable 
safety profile, and the echinocandins are most frequently used as adjunctive therapy due 
to a lack of fungicidal activity against Aspergillus.[10] Thus, the anti-Aspergillus 
triazoles, including voriconazole, isavuconazole, itraconazole, and posaconazole, have 
proven essential to the treatment of invasive aspergillosis, and are commonly relied upon 
for both front-line and salvage therapies. Yet, the emergence isolates of Aspergillus 
fumigatus from both clinical and environmental samples, represents a critical treat to the 
future utility of this crucial class of anti-Aspergillus agents.[5, 6, 8, 37, 52]  
 
Over the last several years, the identification of triazole-resistant A. fumigatus has 
been increasingly reported worldwide. In certain regions such as northern Europe, where 
the rate of triazole-resistant A. fumigatus had previously approximated the global average 
of 5%, resistance rates exceeding 15% are now being reported.[7, 51, 55] While a 
growing body of evidence supports the agricultural use of antifungals as a significant 
contributor to this emergence of resistance, the underlying molecular mechanisms of 
triazole resistance are less well understood.[6, 76-78] The majority of the molecular 
mechanisms of triazole resistance which have been characterized to date involve the 
genes encoding sterol-demethylase, the enzymes which the triazoles competitively 
inhibit.[79] A number of mutations encoding amino acid substitutions in one of the A. 
fumigatus sterol-demethylase enzymes, Cyp51A, are known to decrease triazole 
susceptibility when introduced into susceptible laboratory strains of A. fumigatus.[79]  
 
----------------- 
* Modified from final submission with permission. Rybak JM, Ge W, Wiederhold NP, 
Parker JE, Kelly SL, Rogers PD and Fortwendel JR. Mutations in hmg1, challenging the 
paradigm of clinical triazole resistance in Aspergillus fumigatus. MBio. 2019 Apr 
2;10(2). pii: e00437-19. doi: 10.1128/mBio.00437-19 
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Additionally, mutations altering both cis- and trans-regulatory elements controlling the 
expression of cyp51A have also been shown to contribute to triazole resistance. However, 
in our previous studies we have demonstrated that mutations in cyp51A and 
overexpression of sterol demethylase genes cannot explain the high level of triazole 
resistance observed among many clinical isolates, suggesting the contribution of 
additional mechanisms not yet identified. 
 
 Another common mechanism of triazole antifungal resistance in pathogenic fungi 
is the up-regulation of efflux pump-encoding gene expression. The A. fumigatus genome 
is predicted to contain more than 300 efflux pump-encoding genes, many of which have 
been observed to have their expression induced by exposure to the triazoles.[25, 42-44, 
66] Furthermore, a number of these transporters have been observed to be constitutively 
overexpressed among triazole resistant clinical isolates.[25] In triazole-susceptible 
laboratory strains of A. fumigatus, the individual disruption of six efflux pump genes 
(abcA, abcC, atrF, atrI, mdr1, and mdrA) has been observed to increase triazole 
susceptibility. [25, 42-44, 66] However, only the small molecule transporter gene, abcA, 
has been demonstrated to contribute to triazole resistance when constitutively 
overexpressed in a triazole-susceptible laboratory strain of A. fumigatus. Additionally, 
abcC (also called cdr1B, abcB, and abcG1) is the only transporter gene which has been 
demonstrated to contribute to clinical triazole resistance. Disruption of abcC in a triazole-
resistant clinical isolate of A. fumigatus decreased the itraconazole minimum inhibitory 
concentration (MIC) by greater than 4-fold, while voriconazole and posaconazole 
susceptibility remained unchanged. This clinical isolate was observed to exhibit increased 
constitutive expression of abcC (>5 fold) relative to the susceptible reference strain. 
Efflux pumps have therefore been proven to be a mechanism by which triazole resistance 
is mediated in clinical isolates of A. fumigatus. However, the extent of the contribution of 
overexpression of these transporters to clinical triazole resistance is not known. 
 
In this work, we identify the A. fumigatus efflux pumps with the highest degree of 
homology to C. albicans Cdr1, a well characterized efflux pump known to significantly 
contribute to clinical triazole resistance.[80, 81] We then perform transcriptional profiling 
on a collection of twenty-one highly triazole-resistant clinical isolates of A. fumigatus as 
well as five triazole-susceptible control isolates to identify which of the genes encoding 
the identified efflux pumps are differentially expressed among triazole-resistant isolates. 
Of these genes, abcA and atrI were identified as the candidates of greatest interest, and 
selected for deletion in clinical isolates observed to constitutively overexpress these 
genes using a Cas9-mediated gene transformation system. We subsequently demonstrate 
that the deletion of either abcA or atrI in highly triazole resistant clinical isolates of A. 
fumigatus known to overexpress these efflux pump-encoding genes, is insufficient to 
significantly restore triazole susceptibility. 
 
 
 
 
 
 33 
Materials and Methods 
 
 
Isolates, Media, and Growth Conditions Used 
 
Twenty-one previously characterized multi-triazole-resistant clinical isolates of A. 
fumigatus, and five triazole-susceptible control clinical isolates of A. fumigatus, 
originating from the United States were obtained from the Fungus Testing Laboratory at 
the University of Texas in San Antonio.[8] All clinical isolates were maintained on 
glucose minimal media (GMM) agar at 37°C. Transformants were selected for using 
sorbitol (1.2M) supplemented GMM agar (SMM) containing 150mg/L of hygromycin. 
All conidia were harvested in sterile water from three-day-old growth plates and conidia 
were enumerated visually using a hemocytometer. 
 
 
Transcriptional Profiling 
 
For assessment of the expression of efflux pump-encoding genes of interest in 
clinical isolates, conidia from each isolate were allowed to germinate overnight in 
Aspergillus minimal media incubated at 37°C on an orbital shaker at 250 RPM in 
biological triplicate. Then RNA was isolated by TriZol based extraction from mature 
hyphae following liquid nitrogen crush as previously described.[68] RNA samples were 
purified using the Qiagen® RNeasy kit. Barcoded libraries were prepared and sequenced 
on the Illumina MiSeq platform. Bowtie2 was utilized to create the A. fumigatus Af293 
reference genome index, followed by alignment of RNAseq reads to the reference 
genome by TopHat2. Transcript assemblies will then be generated from the aligned 
RNAseq reads by Cufflinks, and Cuffmerge was utilized to create a single annotated 
transcriptome. Transcript counts from each sample, normalized by reads per kilobase of 
exon length per million mapped reads, were then compared to the triazole susceptible 
control clinical isolate DI-16-6 (voriconazole MIC 0.25mg/L) to obtain fold change 
values. Statistical analysis was performed using unpaired, two-tailed, students t-test in 
Prism 8 for Mac OS by GraphPad Software Inc. with significance set at 0.05 and degrees 
of freedom equal to 10. 
 
 
Construction of Efflux Pump-Encoding Gene Deletion Repair Templates 
 
 Repair templates consisting of the resistance marker (hphR) and 50 bases of 
microhomology targeting the genes of interest were prepared by PCR as previously 
described.[67] Briefly, the hygromycin B resistance cassette, including the gdpA 
promoter and hphR gene was amplified by PCR from the pUCGH plasmid using primers 
that introduced approximately 50 bases of homology with the regions immediately 
upstream and downstream of either the abcA or atrI open reading frame. Subsequently, 
the Gene Clean II Kit (MP Biomedicals) was used to purify PCR products following 
confirmation of product size by gel electrophoresis. Cas9-RNP complexes targeting 
sequences immediately upstream and downstream of the open reading frame of abcA and 
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atrI were assembled as previously described.[67] Target specific primers and guide 
sequences are listed in Table 3-1. 
 
 
Aspergillus Protoplast Transformations 
 
Transformation of A. fumigatus protoplasts were performed as previously 
described with minor modifications.[67] Approximately 2μg of each portion applicable 
transformation repair templates were then mixed with 200 μL of protoplasts, 26.5 μL of 
Cas9-RNP complexes, and 25 μL of polyethylene glycol (PEG)-CaCl2 buffer (60% 
[wt/vol] PEG 3350, 50 mM CaCl2·H2O, 450 mM Tris-HCl, pH 7.5) as previously 
described. Following an incubation on ice for approximately one hour, 1.25mL PEG-
CaCl2 was added and the mixture incubated for an additional 20 minutes at room 
temperature. The mixture was then diluted to a total volume of 3 mL with STC buffer 
(1.2 M sorbitol, 7.55 mM CaCl2·H2O, 10 mM Tris-HCl, pH 7.5) and plated on SMM 
agar plates. Plates were then incubated overnight prior to being overlaid with SMM top 
agar (GMM supplemented with 1.2 M sorbitol and 0.7% [wt/vol] agar) supplemented 
with hygromycin (final concentration of 150 g/ml), and the plates were incubated at 37°C 
for 3 days. Transformants were isolated to separate plates containing selective agar, 
genomic DNA extracted, and successful CRISPR/Cas9 editing confirmed by PCR 
screens using gene-specific primers. 
 
 
Clinical Antifungal Susceptibility Testing 
 
Susceptibilities for voriconazole, isavuconazole, itraconazole, and posaconazole 
were determined for all isolates in accordance with Clinical Laboratory Standards 
Institute (CLSI) M38-A2 methodology utilizing broth microdilution in RPMI in technical 
triplicate.[69] Each antifungal was obtained from the appropriate manufacturer. All 
agents were suspended in dimethyl sulfoxide (DMSO) for preparation of stock solutions. 
 
 
Results 
 
 
Analysis of the Expression of the Efflux Pump-Encoding Genes abcA and atrI 
Among Triazole-Resistant Clinical Isolates 
 
 To identify candidate efflux-pumps encoding genes which may contribute to 
triazole resistance in clinical isolates of A. fumigatus, the genes in the reference Af293 A. 
fumigatus genome with a predicted peptide sequences possessing the highest homology 
to C. albicans Cdr1 were identified by BLASTP. Twelve genes (Table 3-2) were 
identified to have markedly higher homology than any other gene (BLAST P scores 
greater than 800, E values of 0.0, and greater than 35% matching residue identities). Of 
these, four have been previously associated with triazole resistance in A. fumigatus  
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Table 3-1. Oligonucleotides used for abcA and atrI experiments. 
 
Oligo Type Gene Primer Name Sequence (5'- 3') 
PCR Primers 
 abcA abcA KO F CRISPR GTATTTCTTCCTGCCATGACCAGGCAGTCA
TCCCAGAGGTTGAGCTTGCATGCCTGCAGG 
 abcA abcA KO R CRISPR CTATCAGTGCTGCAAGTCATGCAGGGTACA
TATACATCACAGCGCCCTTCCGAGCTCCC 
 atrI atrI KO F CRISPR CCACTGTGGATTCTCGGCATCGTCATTCAT
TTTTCTTCCGAGCTTGCATGCCTGCAGG 
 atrI atrI KO R CRISPR GGCGGCAGGAAAGATGTGGATTTTCTATGT
ATAAGAATAGCGCCCTTCCGAGCTCCC 
 abcA abcA screen F GTTCGACTGTTTATGTGTATACCTATTGTG
ACGCAACCACTCAGCTTGCATGCCTGCAGG 
 atrI atrI screen F GGGTTGATGTTAGGATTTATCGTCCCTAGA
AGAGACATGCTTGGTACCTGTGAAGAAGT
G 
 
 
hphR hphR screen R CAAATCGCCCGCAGAAGCG 
crRNA Guide Sequences 
 abcA abcA 5’ crRNA TGGTGTGAGTCGTGCAGCGA 
 abcA abcA 3’ crRNA CTTATTGCTGTTCGTCAGCT 
 atrI atrI 5’ crRNA ATTATGGGTGTATAGATGAA 
 atrI atrI 5’ crRNA CATGTACACACCCACTATCA 
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Table 3-2. Relative expression of efflux pump-coding genes of interest among triazole-resistant clinical isolates. 
 
  Susceptible Isolates  Resistant Isolates 
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D
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D
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5
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0
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I1
5
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1
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D
I1
5
-1
0
5
 
D
I1
5
-1
0
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D
I1
5
-1
0
8
 
D
I1
5
-9
5
 
D
I1
5
-9
8
 
D
I1
5
-9
6
 
D
I1
5
-1
0
6
 
D
I1
5
-1
2
0
 
Afu2g15130 
(abcA) 
 
0.9 1.4 0.6 1.5 1.0  2.1 2.4 0.6 2.1 0.7 4.2 1.7 2.5 1.8 7.4 19.0 238.6 1.4 15.1 1.3 1.1 2.3 3.3 11.6 6.6 1.8 
Afu1g14330 
(abcC) 
 
0.9 3.1 1.2 1.2 1.5  1.2 0.8 0.8 1.9 0.8 1.4 1.4 1.1 3.1 3.2 3.7 83.4 3.3 2.4 1.9 0.5 1.7 2.4 6.8 4.0 6.3 
Afu1g17440 
 
1.1 0.7 0.7 0.3 0.7  1.3 0.8 0.9 2.2 2.5 1.6 1.1 0.4 1.3 2.1 2.3 3.2 1.7 1.6 2.6 8.7 1.7 1.0 1.1 2.6 1.6 
Afu5g00790 
 
0.8 0.5 0.4 1.4 0.6  0.3 0.3 0.4 0.4 0.2 0.3 0.1 0.2 0.4 0.8 1.5 0.6 0.2 0.2 0.2 1.8 1.1 1.2 0.6 0.5 0.2 
Afu3g07300 
(atrI) 
 
1.1 0.6 0.8 1.3 0.9  2.0 1.4 1.3 1.2 1.7 0.6 1.5 1.9 1.6 2.1 2.2 8.3 1.8 2.0 3.5 1.7 2.0 2.3 4.6 8.1 3.3 
Afu5g02260 
 
0.9 0.6 0.8 0.7 0.5  1.5 0.5 0.5 0.8 0.3 0.7 0.6 0.7 1.5 0.9 0.9 1.1 1.0 0.9 1.1 1.6 1.3 1.6 1.3 1.4 0.6 
Afu6g08020 
 
1.1 1.5 1.3 1.3 1.6  1.8 1.0 1.0 3.2 1.5 5.6 0.9 2.6 1.3 1.1 1.9 3.6 1.3 22.4 7.9 1.1 3.3 3.4 2.4 6.1 1.4 
Afu3g01400 
 
1.1 0.5 0.6 0.5 0.6  0.7 0.5 0.4 0.6 0.6 0.5 0.6 0.6 0.7 0.4 1.3 2.3 0.7 0.5 1.4 1.0 0.7 0.8 1.8 1.7 1.0 
Afu6g04360 
(atrF) 
 
0.9 0.4 2.3 6.9 1.3  2.3 1.4 2.2 4.1 1.6 1.8 1.7 2.3 2.6 2.7 1.2 1.0 3.8 5.3 8.4 4.6 2.0 6.9 4.6 1.6 2.2 
Afu4g01050 
 
1.1 0.3 0.4 0.7 0.6  0.3 0.5 0.8 0.8 0.6 0.6 0.3 0.9 0.3 0.5 0.2 0.8 0.2 1.5 0.5 0.8 0.4 1.4 0.3 0.4 0.5 
Afu5g09460 
 
0.9 0.9 0.9 4.7 1.3  1.1 0.7 0.8 0.9 0.6 0.5 0.2 0.6 1.7 0.3 1.3 0.8 0.4 0.8 0.9 0.8 1.9 0.5 1.4 0.6 0.7 
Afu8g02650 
 
1.1 1.2 1.2 1.2 1.6  0.6 0.8 1.3 1.0 0.9 0.6 0.9 1.2 1.8 1.2 1.4 1.1 1.6 1.6 1.7 1.3 2.2 1.4 1.5 1.7 1.0 
 
A. fumigatus clinical isolates are ordered by escalating voriconazole MIC from left to right. A fumigatus genes are listed by degree of 
homology with C. albicans Cdr1 from top to bottom. Genes shown in bold have previously been associated with triazole resistance in 
A. fumigatus. Fold expression values are shown as the average of three independent biological samples relative to the triazole-
susceptible control isolate DI16-6. Fold expression values shown underlined are the highest for that gene among susceptible isolates. 
Fold expression values among resistant isolates shown in bold are at least two times higher than the highest measured value for the 
same gene among the triazole susceptible control isolates (underlined value).
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(abcA, abcC, atrF, and atrI). Additionally, disruption of abcC has previously been 
demonstrated to increase triazole susceptibility in both susceptible laboratory strains and 
a triazole-resistant clinical isolate. [25, 42-44, 66]  
 
 To assess the whether the constitutive expression of each the identified efflux 
pump-encoding genes of interest may be greater among triazole-resistant clinical isolates 
of A. fumigatus, we obtained twenty-six clinical isolates from the Fungus Testing 
Laboratory in San Antonio, Texas. This collection of isolates includes five triazole-
susceptible clinical isolates, and twenty-one triazole-resistant clinical isolates that have 
MIC for at least two triazole agents above published CLSI epidemiological cut-off values 
(ECV; voriconazole, isavuconazole, and itraconazole 1mg/L, posaconazole 
0.25mg/L).[73, 82] RNA was then isolated from each clinical isolate in biological 
triplicate following overnight growth in Aspergillus minimal media at 37°C on an orbital 
shaker at 250 RPM, and transcriptional profiling was performed. Normalized read counts 
were for each sample were compared to the read counts measured in the triazole-
susceptible control isolate DI16-6 (voriconazole MIC 0.25mg/L) to generate fold change 
values for each of the efflux pump-encoding genes of interest (Table 3-2).  
 
 Of the twelve efflux pump-encoding genes of interest, six were observed to be 
expressed at least 2-fold higher in one or more triazole-resistant isolate, as compared to 
the triazole-susceptible isolate with the highest measured level of expression for each 
gene of interest (abcA, abcC, Afu1g17440, atrI, Afu6g08020, and Afu3g01400). Ten 
resistant isolates were observed to overexpress more than one gene of interest, and this 
was more frequently observed among more highly triazole resistant clinical isolates. 
abcA, which has been shown to increase triazole resistance when overexpressed in a 
triazole-susceptible laboratory strain and which has the highest degree of homology with 
C. albicans Cdr1, was observed to be overexpressed in eight triazole-resistant clinical 
isolates (3.3 to 238.6-fold that of DI16-6). abcC, which has previously been shown to 
contribute to clinical triazole resistance in A. fumigatus, was overexpressed in three 
triazole-resistant clinical isolates (6.3 to 83.4-fold that of DI16-6). Afu1g17440, which 
has not previously been implicated in triazole resistance, was overexpressed in seven 
triazole-resistant clinical isolates (2.2 to 8.7-fold). atrI, which when deleted in a triazole-
susceptible laboratory strain of A. fumigatus leads to hyper-susceptibility, was 
overexpressed in five triazole-resistant isolates (3.3 to 8.3-fold that of DI16-6). 
Afu6g08020 and Afu3g014000 have not previously been associated with triazole 
resistance and were overexpressed in eight (3.2 to 22.4-fold that of DI16-6) and one (2.3 
fold that of DI16-6) triazole-resistant isolates, respectively. As abcA and atrI both have 
previously been implicated in triazole resistance, were both found to be overexpressed in 
multiple triazole-resistant isolates in this collection, and have not yet been demonstrated 
to contribute to triazole resistance among clinical isolates of A. fumigatus, these efflux 
pump-encoding genes were selected for further interrogation. 
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Deletion of the Efflux Pump-Encoding Genes abcA and atrI Has Minimal Impact on 
Clinical Triazole Resistance 
 
 Following the identification of abcA and atrI as the efflux pump-encoding genes 
of greatest interest, we sought to characterize the direct impact of these two genes on 
triazole resistance in clinical isolates of A. fumigatus. To accomplish this, we utilized a 
Cas9-mediated transformation system to delete abcA and atrI in triazole-resistant clinical 
isolates observed to exhibit constitutive overexpression of each of these genes.[67] As 
eight resistant clinical isolates were observed to exhibit overexpression of abcA (at least 
2-fold above the highest expression among triazole-susceptible isolates), and seven of 
these were found to be statistically significant (as compared to DI16-6; Figure 3-1A), we 
selected both DI15-100 (19-fold the abcA expression of DI16-6) and DI15-106 (6.6-fold 
the abcA expression of DI16-6) for deletion of abcA. Importantly, DI15-110 (238.6-fold 
the abcA expression of DI16-6) was not selected as this isolate exhibits a slow growth 
rate, altered growth morphology, and diminished conidiation, all of which make genetic 
manipulations technically challenging. Of the five triazole-resistant isolates observed to 
overexpress atrI (at least 2-fold above the highest expression among triazole-susceptible 
isolates), all of which were statistically significant as compared to DI16-6 (Figure 3-1B), 
DI15-106 (8.1-fold the atrI expression of DI16-6) was selected for deletion of atrI. 
Subsequently, two independent, positive transformants were constructed for each gene of 
interest as previously described.[67] Triazole MIC for all clinically available agents were 
then determined following CLSI methods for the parental triazole-resistant clinical 
isolates and all efflux pump-deletion strains.[69]  
 
 The voriconazole, isavuconazole, itraconazole, and posaconazole MIC for DI15-
100, DI-106, and all derivative efflux pump deletion strains are shown in Table 3-3. For 
both triazole-resistant clinical isolates, the MIC for voriconazole, isavuconazole, and 
itraconazole were greater than previously published ECV. Notably, the voriconazole and 
isavuconazole MIC for DI15-106 were above the CLSI recommended testing range (0.03 
to 16mg/L) and at least 32-fold above the ECV (1mg/L) for these agents.[69] Deletion of 
abcA in either the DI5-100 or DI15-106 clinical isolate backgrounds had no impact on 
isavuconazole or posaconazole MIC. In the abcA deletion strains constructed in the DI15-
100 background (DI15-100_abcA_A and DI15-100_abcA_B), voriconazole MIC were 
reduced by one dilution (8 to 4mg/L). In the abcA deletion strains constructed in the 
DI15-106 background (DI15-106_abcA_A and DI15-106_abcA_B), itraconazole MIC 
were reduced by one dilution (2 to 1mg/L). While these changes in triazole MIC were 
reproducible, they are also within the accepted assay error range.[69] Similarly, MIC for 
voriconazole, isavuconazole, and itraconazole were unchanged upon deletion of atrI in 
the DI15-106 background. Posaconazole MIC were observed to increase by one dilution 
(from 0.125 to 0.25mg/L).  
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Figure 3-1.  Relative expression of abcA and atrI among triazole-resistant clinical 
isolates. 
A) Expression of abcA in clinical isolates relative to triazole-susceptible isolate DI16-6 
B) expression of atrI in clinical isolates relative to triazole-susceptible isolate DI16-6; 
Triazole-susceptible isolates shown as open bars, triazole-resistant isolates shown as 
filled bars. Triazole-resistant isolates shown in order of escalating voriconazole MIC 
from left to right. Horizontal dotted lines denote highest and lowest expression level 
observed among the five triazole-susceptible isolates. Comparisons with the susceptible 
control isolate DI16-6 with statistically significant (p<0.05) results are noted with an 
Asterix. 
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Table 3-3. Triazole MIC of clinical isolates and derivative efflux pump-encoding 
gene deletion strains. 
 
Parent Clinical Isolate or Triazole MIC (mg/L) 
Derivative Strain Voriconazole Isavuconazole Itraconazole Posaconazole 
DI15-100  8 4 4 0.125 
     DI15-100_abcA_A 4 4 4 0.125 
     DI15-100_abcA_B 4 4 4 0.125 
     
DI15-106 ≥32 ≥32 2 0.125 
     DI15-106_abcA_A ≥32 ≥32 1 0.125 
     DI15-106_abcA_B ≥32 ≥32 1 0.125 
     DI15-106_atrI_A ≥32 ≥32 2 0.25 
     DI15-106_atrI_B ≥32 ≥32 2 0.25 
 
MIC shown in bold are greater than epidemiologic cutoff values as published by the 
Clinical Laboratory and Standards Institute (1mg/L for voriconazole and itraconazole; 
0.25mg/L for posaconazole). 
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Conclusions 
 
 In this work we attempted to identify efflux pump-encoding genes which may 
contribute to triazole resistance in clinical isolates of A. fumigatus. We identified twelve 
efflux pump encoding genes in the Af293 reference A. fumigatus genome with predicted 
peptides sequences that have the highest degree of homology with the well characterized 
C. albicans triazole efflux pump Cdr1. Importantly, four of the identified genes of 
interest have previously been associated with triazole resistance, and one of these, abcC, 
has been demonstrated to directly contribute to clinical triazole resistance. [25, 42-44, 66] 
The remaining eight genes have not previously been well characterized.  
 
We then performed transcriptional profiling on a collection of twenty-one multi-
triazole-resistant clinical isolates of A. fumigatus, as well as five triazole-susceptible 
control clinical A. fumigatus isolates, to identify which of these efflux pump-encoding 
genes are constitutively overexpressed among triazole-resistant clinical isolates. 
Transcriptional profiling revealed that six of the twelve efflux pump-encoding genes of 
interest were more highly expressed among triazole resistant isolates. These six genes 
included abcA, abcC, and atrI, which have previously been implicated in triazole 
resistance, as well as Afu1g17440, Afu6g08020, and Afu3g01400 which have not. 
Interestingly, ten triazole-resistant isolates were observed to overexpress two or more 
genes of interest, and this was observed more frequently among isolates which are more 
highly triazole-resistant. Additionally, atrF, which has also previously been implicated in 
triazole resistance, was not observed to be more highly expressed among the triazole-
resistant isolates in this collection.  
 
We subsequently identified both abcA and atrI as the genes of greatest interest for 
further investigation, due to both the observed degree of overexpression among triazole-
resistant isolates in our collection, and the findings of previous studies implicating these 
genes in clinical triazole resistance. Surprisingly, upon deletion of abcA in both the DI15-
100 and DI15-106 triazole-resistant clinical isolate backgrounds, no pronounced change 
in triazole susceptibility was observed. Similarly, when atrI was deleted in the DI15-106 
background, no decrease in triazole resistance occurred. Yet, it remains possible that that 
these highly triazole-resistant clinical isolates harbor multiple triazole resistance 
mechanisms, such as mutations in the sterol-demethylase gene cyp51A, which may mask 
smaller changes in triazole susceptibility upon deletion of the efflux pump encoding 
genes of interest. In fact, in previous studies we have shown that DI15-100 and DI15-106 
both harbor mutations in cyp51A (encoding M263I and TR46/Y121F/T289A, 
respectively). However, we have also demonstrated that correction of these cyp51A 
mutations in DI15-100 and DI15-106 also failed to restore the MIC of any triazole agent 
to wild-type susceptible ranges. 
 
Taken together, the findings of this study serve to demonstrate that A. fumigatus 
efflux pump-encoding genes with homology to known triazole resistance genes are 
constitutively overexpressed among triazole-resistant clinical isolates. However, deletion 
of either abcA or atrI in resistant clinical isolates which constitutively overexpress them 
was insufficient to significantly restore triazole susceptibility. Future studies are needed 
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to further characterize the potential role of these and other A. fumigatus efflux pump-
encoding genes in clinical triazole resistance, the genetic determinants which lead to 
increased efflux pump gene expression among triazole-resistant clinical isolates of A. 
fumigatus.   
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CHAPTER 4.    MUTATIONS IN THE ASPERGILLUS FUMIGATUS HMG-COA 
REDUCTASE GENE, HMG1, A NOVEL GENETIC DETERMINANT OF 
CLINICAL TRIAZOLE RESISTANCE* 
 
 
Introduction 
 
 The most common invasive mold infection is invasive aspergillosis, with 
Aspergillus fumigatus being identified as the etiological agent for more than 72% of all 
cases.[2] Worldwide invasive aspergillosis is implicated in more than 200,000 life- 
threatening infections each year, and is estimated to affect more than 10% of all patients 
with acute leukemia or having received bone marrow or other transplants.[1] While 
substantial healthcare resources are allocated to the treatment of invasive aspergillosis, 
rates of clinical failure remain unacceptably high, approximating 40%.[4, 83, 84] 
 
The triazole class of antifungals are essential to the treatment of invasive 
aspergillosis. Routinely relied upon as both front-line (voriconazole and isavuconazole) 
and salvage (itraconazole and posaconazole) therapeutic options, these agents are 
available in a range of oral and intravenous formulations and generally are well 
tolerated.[10, 13, 79] The triazoles exert fungicidal activity against Aspergillus through 
the inhibition of the biosynthesis of ergosterol, and essential constituent of fungal cell 
membranes.[21] The triazoles impede ergosterol biosynthesis through competitive 
inhibition of the sterol-demethylase proteins, Cyp51A and Cyp51B. Inhibition of these 
two enzymes ultimately leads to a depletion of cellular ergosterol and the accumulation 
of methylated ergosterol precursors.[14] Unfortunately, the treatment of invasive 
aspergillosis has been further complicated by the emergence of A. fumigatus isolates 
resistant to the triazoles. While the rate of triazole resistance in the United States is 
currently estimated to be 5%, globally reports of triazole-resistant A. fumigatus clinical 
isolates are increasing. In countries such as the United Kingdom and the Netherlands, 
where triazole resistance rates were previously comparable to those in the United States, 
resistance rates now exceed 15%.[6-8, 30]  
 
A limited number of triazole resistance mechanisms have been identified in A. 
fumigatus, largely mirroring mechanisms of triazole resistance previously identified in 
other pathogenic fungi such as Candida albicans. Single nucleotide polymorphisms 
(SNPs) resulting in amino acid substitutions in one of the two sterol-demethylase 
enzymes, Cyp51A, overexpression of the gene encoding this sterol-demethylase enzyme, 
cyp51A, and overexpression of the efflux pump-encoding gene, abcC, have all been 
shown to contribute to triazole resistance among clinical isolates of A. fumigatus.[25, 28, 
34, 35, 42-44, 48, 66, 71, 79] However, we have previously demonstrated that these 
 
----------------- 
* Modified from final submission with permission. Rybak JM, Ge W, Wiederhold NP, 
Parker JE, Kelly SL, Rogers PD and Fortwendel JR. Mutations in hmg1, challenging the 
paradigm of clinical triazole resistance in Aspergillus fumigatus. MBio. 2019 Apr 
2;10(2). pii: e00437-19. doi: 10.1128/mBio.00437-19  
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mechanisms alone poorly explain the high level of triazole resistance observed among 
many clinical isolates of A. fumigatus.  Thus, the molecular mechanisms underpinning 
much of the clinical resistance to this essential class of anti-Aspergillus agents remains 
unexplained, limiting the discovery of therapeutic strategies to overcome triazole-
resistant aspergillosis. 
 
We describe here for the first time a novel mechanism of triazole resistance, not 
mediated by mutations in sterol-demethylase and never before observed among 
pathogenic fungi, which was found to be present in a majority of triazole-resistant clinical 
isolates of A. fumigatus in our collection. Mutations in the 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase encoding gene, hmg1 (Afu2g03700), were found to 
result in dramatically increased resistance to all clinically available triazole agents. 
Additionally, the restoration of hmg1 to the wild-type sequence in a clinical A. fumigatus 
isolate exhibiting high-level pan-triazole resistance was found to restore clinical 
susceptibility to the triazole class. We demonstrate that mutations in hmg1 result in 
maintained or even increased ergosterol production as well as accumulation of multiple 
ergosterol precursors, including eburicol, the substrate of the sterol-demethylase enzymes 
which the triazole antifungals competitively inhibit. 
 
 
Materials and Methods 
 
 
Isolates, Media, and Growth Conditions Used  
 
Twenty-one previously characterized multi-triazole-resistant clinical isolates of A. 
fumigatus, and five triazole-susceptible control clinical isolates of A. fumigatus, 
originating from the United States were obtained from the Fungus Testing Laboratory at 
the University of Texas in San Antonio.[8] The laboratory strains akuBKU80 and Af293 
were obtained from the Fungal Genetics Stock Center. All strains and clinical isolates 
used in this study were maintained on glucose minimal media (GMM) agar at 37°C. 
Transformants were selected for using sorbitol (1.2M) supplemented GMM agar (SMM) 
containing 150mg/L of hygromycin. All conidia were harvested in sterile water from 
three-day-old growth plates and conidia were enumerated visually using a 
hemocytometer. 
 
 
Construction of Allele Replacement Repair Templates and Cas9-RNP for the hmg1 
Locus 
 
Two component repair templates consisting of a split hygromycin resistance 
marker (hphR) and hmg1 alleles of interest were prepared by PCR. Briefly, hmg1 alleles 
of interest including the open reading frame and approximately 500 downstream bases 
were amplified by PCR from DI15-98 (S305P), DI15-100 (I412S), DI15-105 (F262del), 
and akuBKU80 (wild-type control) using a 3’ primer which introduced the terminal 80 
bases with homology to the 3’ end of the hphR hygromycin B resistance gene open 
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reading frame. A partial hygromycin B resistance cassette, including the gdpA promoter 
and a truncated hphR gene lacking the terminal 40 bases, was then amplified by PCR 
from the pUCGH plasmid using primers that introduced approximately 70 bases of 
homology with the downstream region of hmg1. PCR products were subsequently 
purified using the Gene Clean II Kit (MP Biomedicals). Cas9-RNP complexes targeting 
sequences immediately upstream and approximately 500 bases downstream of the open 
reading frame of hmg1 were assembled as previously described.[67] Target specific 
guide sequences and primers are listed in Table 4-1.  
 
 
Aspergillus Protoplast Transformations 
 
Transformation of A. fumigatus protoplasts were performed as previously 
described with minor modifications.[67] Approximately 2μg of each portion applicable 
transformation repair templates were then mixed with 200 μL of protoplasts, 26.5 μL of 
Cas9-RNP complexes, and 25 μL of polyethylene glycol (PEG)-CaCl2 buffer (60% 
[wt/vol] PEG 3350, 50 mM CaCl2·H2O, 450 mM Tris-HCl, pH 7.5) as previously 
described. Following an incubation on ice for approximately one hour, 1.25mL PEG-
CaCl2 was added and the mixture incubated for an additional 20 minutes at room 
temperature. The mixture was then diluted to a total volume of 3 mL with STC buffer 
(1.2 M sorbitol, 7.55 mM CaCl2·H2O, 10 mM Tris-HCl, pH 7.5) and plated on SMM 
agar plates. Plates were then incubated overnight prior to being overlaid with SMM top 
agar (GMM supplemented with 1.2 M sorbitol and 0.7% [wt/vol] agar) supplemented 
with hygromycin (final concentration of 150 g/ml), and the plates were incubated at 37°C 
for 3 days. Transformants were isolated to separate plates containing selective agar, 
genomic DNA extracted, and successful CRISPR/Cas9 editing confirmed by PCR 
screens using gene-specific primers and Sanger sequencing. 
 
 
Clinical Antifungal Susceptibility Testing 
 
Susceptibilities for amphotericin B, voriconazole, isavuconazole, itraconazole, 
and posaconazole were determined for all isolates in accordance with CLSI M38-A2 
methodology utilizing broth microdilution in RPMI.[69] Each antifungal was obtained 
from the appropriate manufacturer. All agents were suspended in dimethyl sulfoxide 
(DMSO) for preparation of stock solutions. 
 
 
Comprehensive Sterol Profiling. 
 
Fresh conidial suspensions of each strain to be studied were prepared in saline 
with tween 80 from AMM agar plates. Conidia were grown in 25mL RPMI supplemented 
with 0.2% glucose buffered to pH 7.0 with MOPS for 24 hours in an orbital shaker at 180 
RPM and 35°C. Cells were then flash frozen using liquid nitrogen, dry weights obtained, 
and alcoholic KOH was utilized to extract nonsaponifiable lipids. A vacuum centrifuge 
(Heto) was then used to dry samples, prior to being derivatized by the addition of 200μL  
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Table 4-1. Oligonucleotides used for hmg1, cyp51A, and cyp51B experiments. 
 
Oligo Type  Gene Primer Name Sequence (5'- 3') 
PCR Primers 
 hmg1 hmg1 F GACAGGCGGCTTACACCGCCTCTCCTGCT
CGCCATTTTGTCTATGATCACTGATGGCT
ACCTCTCTGATT 
 hmg1 hmg1 split hphR R TCTGGACCGATGGCTGTGTAGAAGTACT
CGCCGATAGTGGAAACCGACGCCCCAGC
ACTCGTCCGAGGGCAAAGGAATAGGCTG
CGTTACTCGGTCTTGG 
 hphR hphR split F CCACTATCGGCGAGTACTTCTACAC 
 hphR hphR 3’UTR hmg1 R CCCACCTGGGATGAAGCAAAAGCGGGTA
CATAGATAGGTTTATGGGGACTTTGGGA
AGTGAAATATGGGCGAGCTCCCAAATCT
GTCCAG 
 hmg1 hmg1 screen F GGTGTCCGTGGTTCCCACC 
 
 
hphR hphR screen R CAAATCGCCCGCAGAAGCG 
crRNA Guide Sequences 
 hmg1 hmg1 5’ crRNA ATTTTGTCTATGATAGACAA 
 
 
hmg1 hmg1 3’ crRNA CCAACGATTGCCAAAGGTCA 
RTqPCR Primers 
 cyp51A cyp51A RT F e1 CTTCTTTGCGTGCAGAGA 
 cyp51A cyp51A RT R e2 GGGGTCGTCAATGGACTA 
 cyp51B cyp51B RT F e1 CTTTTTCGACTGCCGCGC 
 cyp51B cyp51B RT R e2 AGGCGTAGTGAGTGGAGA 
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of anhydrous pyridine (Sigma), 100μL of N,O- bis(trimethylsilyl)trifluoroacetamide 
(BSTFA)- 10% trimethylsilyl (TMS) (Sigma), and two hours of heating at 80C. Gas 
chromatography-mass spectrometry (GC-MS) (Thermo 1300 GC coupled to a Thermo 
ISQ mass spectrometer; Thermo Scientific) was then used to analyze and identify TMS- 
derivatized sterols. Known standards were referenced for fragmentation spectra and 
retention times. Sterol profiles for each isolate were then created using Xcalibur software 
(Thermo Scientific) to analyze GC- MS data.[16] Statistical analysis of both sterol 
profiles and total ergosterol per dry weight were performed using GraphPad Prism 7. In 
all cases, 6 independent biological replicates were measured and included in analysis, 
two-tailed unpaired t-test were performed in Prism 8 for Mac OS by GraphPad Software 
Inc. with significance set at 0.05 and degrees of freedom equal to 10. 
 
 
Assessment cyp51A and cyp51B Expression by RTqPCR 
 
Conidia from each strain were allowed to germinate overnight on an orbital 
shaker at 250 RPM incubated at 37°C in Aspergillus minimal media. RNA was then 
extracted from mature hyphae following liquid nitrogen crush as previously 
described.[68] cDNA was synthesized using the RevertAid RT kit (Thermo Scientific). A. 
fumigatus cyp51A and cyp51B were amplified from cDNA by PCR using PCR master 
mix and SYBR per the manufacturer’s instructions. Table 4-1 lists the gene specific 
primers used for PCR. Conditions used for PCR were as follows: AmpliTaq Gold 
activation at 95°C for 10 minutes, 40 cycles of denaturation at 95°C for 15 seconds and 
annealing/ extension at 60°C. The dissociation curve and threshold cycle (CT) was 
determined using the CFX96 Real Time PCR system (Bio-Rad). Changes in gene 
expression among isolates were then calculated using the 2-ΔΔCT method. All 
experiments were performed in triplicate from biological triplicates. As previously 
described, ΔCT values were used to calculate the standard error.[68] Statistically analysis 
was performed using unpaired, two-tailed, students t-test in Prism 8 for Mac OS by 
GraphPad Software Inc. with significance set at 0.05 and degrees of freedom equal to 10. 
 
 
Results 
 
Mutations in hmg1 Are Common Among Triazole-Resistant Clinical Isolates of A. 
fumigatus 
 
Following our prior findings that the previously characterized mechanisms of 
triazole-resistance did not explain the high level of triazole resistance observed in this 
collection of clinical A. fumigatus isolates, we sought to interrogate the previously 
generated whole genome sequencing data to identify novel mechanisms of resistance. As 
the triazoles exert antifungal activity through the inhibition of biosynthesis of the 
predominant fungal membrane sterol, ergosterol, initial whole genome sequencing 
analysis targeted genes encoding proteins known to participate in ergosterol biosynthesis. 
In addition to the previously identified cyp51A mutations, mutations unique to triazole-
resistant isolates were also observed in erg3B (Afu2g00320), erg3C (Afu8g01070), 
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erg4B (Afu1g07140), erg5 (Afu1g03950), and erg6 (Afu4g03630). However, mutations 
occurred in these genes among only a small number of the clinical isolates (Table 4-2). 
Intriguingly, 11 of the 21 triazole-resistant clinical isolates (52%) were found to possess 
mutations in the hmg1 gene resulting in peptide sequence changes not observed among 
the triazole-susceptible control isolates (Figure 4-1A). The A. fumigatus hmg1 gene 
encodes a HMG-CoA reductase enzyme previously reported to be essential. HMG-CoA 
reductase catalyzes the first committed step in ergosterol biosynthesis and has previously 
been shown in other eukaryotic organisms to participate in the regulation of sterol 
biosynthesis through direct interactions between sterols and a conserved sterol sensing-
domain.[85-88] Of particular interest, eight of the eleven isolates with hmg1 mutations 
were found to have mutations affecting residues predicted to reside within the conserved 
sterol-sensing domain of Hmg1 (Figure 4-1B). We additionally accessed publicly 
available whole genome sequencing data for 11 triazole-resistant clinical isolates 
(https://www.ebi.ac.uk/arrayexpress/experiments/E-SYBR-1/samples/) and found 5 to 
have mutations in hmg1, 2 of which alter residues in the predicted sterol sensing domain 
(P309L and I412T). As mutations in hmg1 were observed in a large proportion of clinical 
triazole-resistant isolates, and hmg1 mutations have previously been observed among 
laboratory isolates of A. fumigatus grown in the presence of triazole antifungals and the 
closely related agricultural sterol-demethylase inhibitors, the observed mutations in hmg1 
were selected for further interrogation.[47, 89] 
 
 
Mutations in hmg1 Confer Resistance to the Triazole Class of Antifungals 
 
To test the hypothesis that mutations in hmg1 directly contribute to clinical 
triazole resistance in A. fumigatus, three mutations encoding amino acid substitutions or 
in-frame codon deletions in different transmembrane regions of the predicted hmg1 
sterol-sensing domain (F262del, S305P, and I412S) were selected for characterization 
(Figure 4-1B). Each of these mutations and a wild-type control allele were directly 
introduced to the native hmg1 locus of the triazole-susceptible laboratory strain akuBKU80 
using a novel Cas9-RNP editing technique incorporating a split hygromycin B resistance 
marker (Figure 4-2). Briefly, hmg1 alleles including the open reading frame and 
approximately 500 downstream bases were amplified by PCR from DI15-98 (S305P), 
DI15-100 (I412S), DI15-105 (F262del), and akuBKU80 (wild-type control) using a 3’ 
primer which introduced the terminal 80 bases with homology to the 3’ end of the hphR 
hygromycin B resistance gene open reading frame. A partial hygromycin B resistance 
cassette, including the gdpA promoter and a truncated hphR gene lacking the terminal 40 
bases, was then amplified by PCR from the pUCGH plasmid using primers that 
introduced approximately 70 bases of homology with the downstream region of 
hmg1.[90] Protoplasts of akuBKU80 were then transformed with RNP complexes, 
consisting of Cas9 protein and crRNA-trRNA duplexes targeting sequences immediately 
upstream and and approximately 500 bases downstream of the open reading frame of 
hmg1, and 2μg of each portion of the split marker repair template (a single hmg1 allele 
and the truncated hygromycin B resistance cassette), to produce hmg1 mutant strains 
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Table 4-2. Mutations in genes involved in ergosterol biosynthesis which are unique to triazole resistant isolates. 
 
Isolate 
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D
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8
 
D
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5
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2
0
 
erg3A - - - - - - - - - - - - - - - - - - - - - 
erg3B H40R - - - - H40R - - - - - - - L88P - - - - - - L88P 
erg3C - 
P197fs, 
R203S, 
I205V, F252I, 
Q310H 
- - - - P317S - - 
P197fs, 
R203S, 
I205V, F252I, 
Q310H 
- - - - - - - P317S - - - 
erg4A - - - - - - - - - - - - - - - - - - - - - 
erg4B D42H - 
T90I, 
H93N, 
H97N 
- H97N D42H - - 
H97N, 
A505S 
- - D42H - - D42H - D42H - - - - 
erg5 - K363R F68L - - - - - - K363R - - - - - - - K363R - - - 
erg6 - - - - - - - - F148C - - - - - F311del M187L - A291T L234I - - 
erg25A - - - - - - - - - - - - - - - - - - - - - 
erg25B - - - - - - - - - - - - - - - - - - - - - 
hmg1 I412S 
G466V, 
S541G 
S305P, 
V995I 
S305P - I412S E105K - F262del - - Y250H V995I L413P - G307D - - - - - 
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Figure 4-1. Mutations in hmg1 observed in this collection of triazole-resistant 
clinical A. fumigatus isolates. 
A) hmg1 mutations observed in each clinical isolate relative to the Af293 reference 
genome, with mutations affecting residues predicted to reside within the conserved sterol-
sensing domain shown in bold. B) Schematic depicting the predicted transmembrane 
domains of A. fumigatus Hmg1. Residues in light blue comprise the predicted sterol-
sensing domain, residues in dark blue represent those affected by hmg1 mutations 
observed in this collection of clinical isolates, residues shown in green represent those 
affected by hmg1 mutations observed in this collection of clinical isolates and further 
characterized in this work. 
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Figure 4-2. Schematic of Cas9 ribonucleoprotein (RNP) editing technique 
incorporating a split hygromycin B resistance marker for creation of hmg1 mutant 
strains. 
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akuBKU80_hmg1F262del, akuBKU80_hmg1S305P, akuBKU80_hmg1I412S, and akuBKU80_hmg1WT.  
 
Antifungal susceptibility testing was subsequently performed for akuBKU80 and 
each of the derivative strains for voriconazole, isavuconazole, itraconazole, posaconazole 
and amphotericin B according to the Clinical Laboratory Standards Institute M38-A2 
standards (Figure 4-3A).[69] The parental akuBKU80 strain was susceptible to all agents 
with MIC of 0.25, 0.5, 0.125, 0.06, and 0.5 mg/L for voriconazole, isavuconazole, 
itraconazole, posaconazole, and amphotericin B, respectively. The akuBKU80_hmg1WT 
control strain exhibited MIC exactly matching those of the parental strain. Conversely, all 
strains harboring a clinically derived mutation in hmg1 were found to exhibit a 4 to 8-fold 
increase in MIC for all tested triazoles, exceeding the CLSI reported epidemiologic cut-
off values for at least one agent in each mutant strain.[73, 82] Notably amphotericin B 
MIC were observed to decrease by two-fold in both the akuBKU80_hmg1S305P and 
akuBKU80_hmg1F262del strains (0.5 versus 0.25mg/L), but not in akuBKU80_hmg1I412S.  
 
In an effort to delineate the extent of hmg1-mutation-mediated triazole resistance 
within a clinical isolate from our collection, the mutant hmg1 allele in the pan-triazole-
resistant clinical isolate DI15-105 was replaced with the wild-type hmg1 allele from 
akuBKU80 using the same Cas9-RNP-mediated gene editing described above. The 
resultant DI15-105_hmg1WT strain exhibited complete restoration of triazole 
susceptibility with an eight-fold or greater decrease in MIC for each triazole agent 
(Figure 6b). Intriguingly, the amphotericin B MIC was observed to increase by two-fold 
in DI15-105_hmg1WT relative to DI15-105 (0.125 versus 0.25mg/L). 
 
 
Mutations in hmg1 Lead to Accumulation of Ergosterol Precursors 
 
As the sterol-sensing domain of HMG-CoA reductase has previously been shown 
to interact with ergosterol precursors and participate in the negative regulation of HMG-
CoA reductase activity in both human cells and the model fission yeast 
Schizosaccharomyces pombe, we hypothesized that the mutations identified in the sterol 
sensing domain of A. fumigatus hmg1 may be leading to dysregulation of the ergosterol 
biosynthesis pathway resulting in the observed triazole resistance (Figure 4-4A).[85-88] 
To test this hypothesis, comprehensive sterol profiling including assessment of the 
relative distribution of cell sterols and the measurement of total ergosterol content per dry 
weight was performed on akuBKU80, akuBKU80_hmg1F262del, akuBKU80_hmg1S305P, 
akuBKU80_hmg1I412S, akuBKU80_hmg1WT. 
 
To assess the relative distribution of sterols among A. fumigatus harboring hmg1 
mutations, freshly harvested conidia stocks of each strain were grown in six biological 
replicates in RPMI media supplemented with 0.2% glucose and buffered with MOPS (pH 
7.0) for 24 hours before cells were flash frozen with liquid nitrogen, dry weights were 
obtained, and nonsaponifiable lipids were extracted, derivatized, and analyzed by gas- 
chromatography mass spectrometry as described previously.[16, 91] In agreement with 
the hypothesis that mutations in hmg1 precipitate dysregulation of the ergosterol 
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Figure 4-3. Impact of hmg1 mutations on antifungal susceptibility. 
A) Triazole MIC for akuBKU80 and derivative mutant hmg1 strains B) Triazole MIC for 
DI15-105 and derivative hmg1WT strain. 
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Figure 4-4. Relative distribution of sterols and total ergosterol content of hmg1 
mutant strains. 
A) A. fumigatus ergosterol biosynthetic pathway B) Relative fold change of cellular 
sterols lanosterol, eburicol, 4,4-dimethyl ergosta 8,24(28) dienol, fecosterol, episterol, 
and ergosterol in hmg1 mutant strains as compared to the parental akuBKU80 strain C) 
Total cellular ergosterol per dry weight for hmg1 mutant strains and the parental 
akuBKU80 strain. Comparisons with the susceptible parental isolate akuBKU80 with 
statistically significant (p<0.05) results are noted with an Asterix. 
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biosynthetic pathway, the distribution of sterols was dramatically altered in all hmg1 
mutant strains relative to akuBKU80 (Figure 4-4B). Most notably, a significant decrease in 
the relative proportion of ergosterol, along with corresponding increases in the 
proportions of several ergosterol precursors downstream of Hmg1, including eburicol, 
4,4-dimethyl ergosta 8,24(28) dienol, and fecosterol, were observed in all mutant hmg1 
strains. Additionally, the relative proportion of episterol was observed to be significantly 
elevated in akuBKU80_hmg1F262del and akuBKU80_hmg1S305P. Importantly, no significant 
differences in the relative distribution of sterols was observed between akuBKU80 and 
akuBKU80_hmg1WT (not shown). 
 
 While the distribution of cellular sterols among A. fumigatus harboring hmg1 
mutations demonstrated a significant decrease in the relative proportion of cellular 
ergosterol, total ergosterol content per dry weight was not lower among any of the mutant 
hmg1 strains (Figure 4-4C). In fact, relative to the parental akuBKU80, 
akuBKU80_hmg1F262del was observed to exhibit a significant increase in total ergosterol 
(4.56 v. 7.06 μg ergosterol/ mg dry weight; p<0.01). Taken together, these findings 
demonstrate hmg1 mutations precipitate a relative increase in ergosterol precursors 
downstream of Hmg1, while maintaining or in some cases even increasing cellular 
ergosterol, leading to significantly altered cellular sterol profiles among mutant hmg1 
strains. 
 
 
Mutations in hmg1 Do Not Lead to Increased Expression of Sterol-Demethylase 
Genes 
 
 As our sterol profiling studies revealed significant accumulations of ergosterol 
precursors both upstream and downstream of sterol-demethylase, and we had previously 
observed that increased expression of either sterol-demethylase gene contributes to 
triazole resistance, we sought to investigate if the triazole resistance associated with 
mutations in hmg1 were at least in part mediated by altered expression of sterol-
demethylase genes. To accomplish this, conidia suspensions of akuBKU80, 
akuBKU80_hmg1F262del, akuBKU80_hmg1S305P, akuBKU80_hmg1I412S, and akuBKU80_hmg1WT 
were grown in biological triplicate under the same conditions used for sterol profile 
analysis, and RNA was extracted from liquid nitrogen-pulverized samples, as previously 
described.[68] RTqPCR was then performed to assess expression of the sterol-
demethylase genes cyp51A and cyp51B among mutant hmg1 strains relative to the 
parental akuBKU80. No significant differences in expression of either sterol-demethylase 
gene was observed for any of the mutant hmg1 strains or the akuBKU80_hmg1WT control 
strain (Figure 4-5). Demonstrating that while mutant hmg1 strains are observed to have 
relatively greater proportions of ergosterol precursors, expression levels of both cyp51A 
and cyp51B remain unchanged. Thus, resistance in these strains is not due to increased 
expression of these genes. 
 
 
 57 
 
 
Figure 4-5. Expression of sterol-demethylase genes is not elevated among mutant 
hmg1 strains. 
Fold expression of cyp51A and cyp51B in mutant hmg1 strains relative to the parental 
akuBKU80 strain as determined by reverse transcription quantitative PCR. 
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Conclusions 
 
 Here we describe for the first time, a novel and non-canonical mechanism of 
triazole antifungal resistance. Identified through whole genome sequencing, mutations in 
the HMG-CoA reductase encoding gene, hmg1, were found among the majority of 
triazole-resistant A. fumigatus clinical isolates in our collection. Of the observed 
mutations, most occurred in the conserved sterol sensing domain of hmg1, which has 
been previously demonstrated to participate in the regulation of sterol biosynthesis in 
other eukaryotic organisms including S. pombe.[85-88]  When three of these clinically-
derived hmg1 mutations were independently introduced into a well characterized triazole-
susceptible strain of A. fumigatus using an optimized Cas9-mediated system to replace 
the native hmg1 locus, resistance to all clinically available anti-Aspergillus triazole 
antifungals greatly increased. To confirm that mutations in hmg1 are a novel mechanism 
of clinical triazole resistance, we employed the same system to correct a hmg1 mutation 
identified in a pan-triazole resistant clinical isolate of A. fumigatus and observed 
restoration of susceptibility to all triazoles.  
 
As the sterol-sensing domain of HMG-CoA reductase has been shown to be 
essential to the regulation of sterol biosynthesis, we hypothesized that amino acid 
substitutions in this domain of Hmg1 may lead to impaired negative regulation of Hmg1 
activity. [85-88] In an effort to test this hypothesis, we performed comprehensive sterol 
profiling on the mutant hmg1 strains. This analysis identified significant accumulations of 
ergosterol precursors, including eburicol, 4,4-dimethyl ergosta 8,24(28) dienol, 
fecosterol, episterol, while total cellular ergosterol content was seen to be maintained, or 
in the case of the hmg1F262del mutation, significantly increased. However, this increase in 
ergosterol precursors did not result in a subsequent increase in sterol-demethylase 
expression levels in any of the mutant hmg1 strains. Thus, hmg1 mutation-mediated 
triazole resistance is not the result of increased sterol-demethylase gene expression.  
 
Taken together, the results of this study identify mutations in the A. fumigatus 
HMG-CoA reductase gene, hmg1, as a novel and non-canonical genetic determinant of 
clinical triazole resistance, present among a large proportion of resistant clinical isolates. 
While the exact mechanism by which mutations in the sterol-sensing domain of hmg1 
impart clinical triazole resistance remains unknown at this time, it is tempting to 
speculate that the negative regulation of Hmg1 activity, which has been shown to be 
dependent on the sterol-sensing domain in other eukaryotic organisms, may be altered by 
residue substitutions in the sterol-sensing domain of A. fumigatus Hmg1. 
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CHAPTER 5.    DISCUSSION 
 
 
 Invasive aspergillosis is a leading cause of morbidity and mortality among 
immunocompromised populations and is predicted to cause more than 200,000 life-
threatening infections each year.[1, 4, 83, 84] Aspergillus fumigatus is the predominant 
pathogen isolated from patients with invasive aspergillosis, and accounts for more than 
60% of all cases.[2] Only three classes antifungal agents are currently available for the 
treatment of invasive infections caused by Aspergillus fumigatus. Of these, the triazoles 
represent both therapeutic agents of choice, such as voriconazole and isavuconazole, as 
well as agents commonly used for salvage therapies such as itraconazole and 
posaconazole. As other antifungal agents such as the polyene amphotericin B and the 
echinocandins possess limitations in formulation, safety profile, or lack consistent 
fungicidal activity against A. fumigatus, the triazoles have proven to be essential to the 
treatment of invasive aspergillosis. Thus, the recent emergence of triazole-resistant A. 
fumigatus represents a critical threat to the current treatment of invasive aspergillosis.[10]  
 
While considerable research has been performed to interrogate the mechanisms by 
which A. fumigatus becomes resistant to triazole antifungals, the overwhelming majority 
of resistance has been ascribed to three canonical paths that were originally described 
among pathogenic fungi decades ago; 1) mutations in sterol-demethylase genes, 2) 
overexpression of sterol-demethylase genes, or 3) overexpression of efflux pump-
encoding genes. [25, 28, 34, 35, 42-44, 48, 66, 71, 79] Of these three paths, mutations in 
the A. fumigatus sterol demethylase gene cyp51A are the most commonly reported in the 
literature. However, the proportion of clinical triazole resistance explained by these 
canonical pathways remains poorly characterized. Additionally, resistant clinical isolates 
exhibiting none of these previously identified mechanisms have been reported.[25] This 
gap in the current understanding of the molecular mechanisms underpinning clinical 
triazole resistance in A. fumigatus is a significant barrier to the preservation of the utility 
of the triazoles and the design of novel therapeutic strategies to overcome triazole-
resistant aspergillosis. The overall objective of this work was to overcome this barrier by 
performing a comprehensive characterization of the direct contributions of previously 
identified mechanisms of triazole resistance in a large collection of highly triazole-
resistant clinical A. fumigatus isolates, and to identify novel mechanisms where 
unexplained clinical resistance was found.  
 
 In Chapter 2 we sought to test the hypothesis that the previously identified 
mechanisms of triazole resistance do not fully account for the degree of triazole 
resistance observed among clinical isolates of A. fumigatus. To accomplish this, we 
utilized a large collection of triazole-resistant clinical A. fumigatus isolates and whole 
genome sequencing, to identify all mutations in the sterol-demethylase genes cyp51A and 
cyp51B, and well the previously identified sterol-demethylase cis- and trans-regulatory 
elements. While no mutations unique to resistant isolates were identified in cyp51B, 
unique mutations in cyp51A were found in the vast majority of resistant isolates. 
However, correction of ten of these cyp51A mutations to the wild-type sequence only 
partially or fully restored clinical triazole susceptibility in two and one clinical isolate 
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background, respectively. Additionally, RTqPCR revealed significant overexpression of 
cyp51A was observed in eight of the twenty-one triazole resistant isolates, five of which 
had mutations in either the promoter of cyp51A or a known transcriptional regulator of 
cyp51A (hapE). However, we subsequently demonstrated that the constitutive 
overexpression of either sterol-demethylase gene by as much as thirty-five-fold, had a 
limited impact on triazole susceptibility in a triazole-susceptible laboratory isolate. Next, 
we examined the expression of the previously characterized A. fumigatus triazole efflux 
pump abcC in our collection of isolates by RTqPCR. Fourteen of the twenty-one triazole-
resistant clinical isolates were observed to have significantly increased expression of 
abcC. However, the majority of these isolates only exhibited a small increase in abcC 
(2.4 to 4.1-fold) while only three were found to have more marked increases in 
expression (6.5 to 33.2-fold), and constitutive overexpression of abcC (7.8-fold) in a 
triazole-susceptible laboratory strain yielded no change in triazole susceptibility. These 
findings serve to highlight the fact that even when considered collectively, the previously 
characterized mechanisms of resistance do not adequately explain the triazole resistance 
observed in this collection of A. fumigatus clinical isolates, and additional mechanisms 
yet to be identified are likely present in this collection.  
 
 Subsequently, in Chapter 3 we tested the hypothesis that the constitutive 
overexpression of efflux pump-encoding genes, other than abcC, directly contributes to 
clinical triazole resistance in A. fumigatus. To accomplish this, we utilized the collection 
of clinical A. fumigatus isolates we had previously characterized and transcriptional 
profiling to identify a subset of A. fumigatus efflux pump-encoding genes with a high 
degree of homology to the well characterized C. albicans triazole efflux pump Cdr1, 
which were uniquely, constitutively overexpressed among triazole-resistant clinical 
isolates. We then identified abcA and atrI as the genes of greatest interest, and utilized 
Cas9-mediated genetic manipulations to delineate the direct contributions of these genes 
to triazole resistance. Unexpectedly, we found that deletion of these genes in triazole-
resistant clinical isolates known to overexpress them, did not to result in meaningful 
changes in triazole susceptibility. However, it is worth noting that these results may have 
been limited by the presence of additional resistance mechanisms in these isolates, such 
as cyp51A mutations. While these findings could not definitively demonstrate a role for 
either abcA or atrI in clinical triazole resistance, they do serve to demonstrate the 
potential for additional efflux pump-encoding genes to participate in clinical triazole 
resistance. 
 
 Finally, in Chapter 4 we utilized our previously generated whole genome 
sequencing data to test the hypothesis that mutations in genes involved in the 
biosynthesis of ergosterol, other than sterol-demethylase, significantly contribute to 
clinical triazole resistance. Following careful examination of our whole genome 
sequencing data, we identified numerous genes of the ergosterol biosynthesis pathway 
(erg3B, erg3C, erg4B, erg5, erg6, and hmg1) where mutations unique to triazole-resistant 
isolates were present. Of these, we found mutations in the HMG-CoA-reductase gene 
hmg1 to be the most intriguing, as the majority of resistant clinical isolates in our 
collection were observed to have mutations in this gene, and previous studies in other 
eukaryotic organisms such as Schizosaccharomyces pombe have found hmg1 homologs 
 61 
to contain conserved sterol sensing domains involved in the regulation of the ergosterol 
biosynthesis pathway. Additionally, the majority of the identified hmg1 mutations were 
found to reside in the predicted sterol-sensing domain. As these sterol-sensing domain 
mutations each fell within one of three predicted transmembrane domains, we selected 
one representative mutation from each transmembrane domain and utilized a novel Cas9-
mediated split marker transformation system to introduce these mutant hmg1 alleles into 
a triazole-susceptible laboratory strain of A. fumigatus. Surprisingly, introduction of each 
of the three mutant hmg1 alleles to the susceptible stain were found to dramatically 
increase MICs for all clinically available triazole agents. Moreover, the complementary 
experiment correcting the F262del hmg1 mutation in the hmg1 allele of the pan-triazole-
resistant isolate DI15-105 resulted in the restoration of clinical susceptibility to all 
triazoles. Thus, proving that mutations in hmg1 are a novel genetic determinant of 
clinical triazole resistance in A. fumigatus.  
 
 As the sterol-sensing domain of HMG-CoA-reductase enzymes has been shown to 
participate in the autoregulation of HMG-CoA-reductase activity, and subsequently the 
regulation of ergosterol biosynthesis, we then hypothesized that mutations in the sterol-
sensing domain of hmg1 lead to dysregulation of ergosterol biosynthesis. To test this 
hypothesis, we performed compressive sterol profiling on the cellular extracts from each 
of our mutant hmg1 strains and the parental strain with a wild-type hmg1 allele. In 
agreement with our hypothesis, sterol profiling revealed that the mutant hmg1 strains 
indeed exhibited accumulation of ergosterol precursors downstream HMG-CoA-
reductase activity, while also maintaining, or in some cases increasing, the total cellular 
ergosterol content. This finding was particularly intriguing as it is suggestive of a 
potential association between increased hmg1 activity and triazole resistance. 
Additionally, HMG-CoA is a validated target for pharmalogical inhibition, and numerous 
drugs which inhibit the human form of this enzyme are currently clinically available. 
Future studies are needed to further characterize the role of hmg1 mutations in clinical 
triazole resistance, and to identify any potential therapeutic strategies for overcoming 
triazole resistance associated with these mutations. 
 
 While the findings of the studies described herein identify mutations in hmg1 as a 
novel genetic determinant of clinical triazole resistance, we have yet to definitively 
identify the molecular mechanism(s) by which these mutations contribute to the observed 
resistance. It is however tempting to speculate, based upon these data and previously 
published findings, that triazole resistance may be the result of two molecular 
mechanisms related to altered cell sterol composition. First, the accumulation of 
ergosterol precursors such as eburicol, episterol, and fecosterol, as observed in our sterol 
profiling experiments, may alter baseline cell membrane characteristics sufficiently to 
diminish the impact of sterol-demethylase inhibition. It has been postulated that a portion 
of the antifungal effect of triazoles is a consequence of acute changes in membrane 
characteristics such as fluidity and integrity upon inhibition of sterol-demethylase 
activity. [92] Accumulation of ergosterol precursors, particularly those downstream of the 
sterol-demethylase enzymes such as episterol and fecosterol, may augment the impact of 
the triazoles on membrane characteristics by either temporarily facilitating continued 
ergosterol biosynthesis or through the modification of baseline membrane characteristics. 
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Additionally, it is possible that the accumulation of ergosterol precursors indirectly 
mediates triazole resistance. Previous studies have shown that the accumulation of sterols 
such as eburicol can precipitate activation of stress response pathways similar to those 
triggered by exposure to triazole antifungals. [93] Thus, the accumulation of ergosterol 
precursors in isolates with mutations in hmg1 may lead to increases in the constitutive 
expression of drug resistance effectors, such as efflux pump-encoding genes, and prime 
cells to rapidly respond to triazole exposure. However, future studies will be needed to 
explore the potential contribution of these molecular mechanisms to hmg1 mutation-
mediated clinical triazole resistance. 
 
 In conclusion, the findings of the work described herein serve to demonstrate that 
clinical triazole resistance in A. fumigatus is most likely the result of a complex 
amalgamation of resistance mechanisms, including both mechanisms currently known 
and yet to be identified. Furthermore, the paradigm of the molecular mechanisms of 
triazole resistance established in fungal pathogens such as Candida albicans, offers only 
an incomplete explanation for the triazole resistance observed in clinical isolates of A. 
fumigatus. The addition of hmg1 mutations to the known genetic determinants of triazole 
resistance advances our understanding of the molecular mechanisms underpinning 
clinical triazole resistance, yet a substantial proportion of resistance remains to be 
explained. Future directions for this work include the characterization of compounded 
triazole resistance mechanisms, such as the combination of cpy51A and hmg1 mutations, 
as well as the further characterization of efflux pump-encoding genes which are 
differentially expressed among triazole-resistant clinical isolates. Additionally, A. 
fumigatus Hmg1 must be investigated as a potential target of pharmacological inhibition 
and an opportunity to for the development of a new therapeutic strategy to overcome 
clinical triazole resistance in A. fumigatus.   
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